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Abstract 
 
The development of therapeutic dosage (e.g. pharmaceutical) systems is an ongoing process 
which, in recent times has incorporated several emerging disciplines and themes at timely 
intervals. While the concepts surrounding dosages have developed and evolved, many 
polymeric excipients remain as the preferred choice of materials over existing counterparts, 
serving functions as matrix materials, coatings and providing other specific functional 
properties (e.g. adhesion, controlled release and mechanical properties). Therefore, polymer is 
employed as a matrix carrier of materials or as active release performance modulating agents 
for polymeric based dosages.  
There have been, however, developments in the deployment of synthetic polymeric materials 
(e.g. polycaprolactone, poly lactic co-glycolic acid) when compared to naturally occurring 
materials (e.g. lactose, gelatin). Additionally, numerous techniques have been advanced further 
to novel engineering polymeric structures which provide materials in micrometer to nanometer 
scale range.  
Some of these structures enabling technologies include spray drying, super critical processing, 
microfluidics and even wet chemical methods. Recently maturing processes which is 
operational at the ambient environment is electrohydrodynamic (EHDA) engineering methods 
(ES and ESy). They have emerged as robust technologies offering potential to fabricate a 
plethora of generic structures directly into a fibrous polymer matrix system (e.g. particles, 
fibres, bubbles and pre-determined patterns) on a broad scale range.  
This research focuses on key developments using EHDA technology for the pharmaceutical 
and biomaterial remits when selecting synthetic and/or naturally occurring polymers as 
pharmaceutical (and therapeutic) excipients. EHDA was employed to engineer NSAID drugs 
in fibre film form for buccal delivery. EHDA was selected to develop fibre film of 
Indomethacin, Diclofenac Sodium, Ketoprofen, and Piroxicam in cooperation of PVP, Ethocel, 
Methocel, HPMC, and Tween 80.  
Morphology of electrospun films were analyzed by SEM and further characterized using DSC, 
TGA, FTIR, Raman and XRD. DSC and XRD demonstrated NSAID drugs change from 
crystalline to amorphous state. FTIR and Raman data suggest NSAID, PVP and co-polymers 
(Methocel™ E5, Methocel™ E15 Ethocel™ E10, HMPC and Tween® 80) were integrated in 
stable fashion into filamentous structures via ES.  
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The release behaviour from several matrixes that was observed suggesting a potential route to 
modify drug release based on polymeric excipients. Therefore, identifying co-polymers in 
matrix and their effect in vitro release was the main core of chapter 3. Based on the results (fast 
or slow release), the co-polymer was incorporated with several NSAID drugs. However, each 
NSAID drugs show different release behaviour with same co-polymer. 
In addition, the underlying EHDA process principles are discussed along with key parameters 
and variables (both materials and engineering). EHDA technologies are operational at ambient 
conditions and recent developments have also demonstrated their viability for large scale 
production. These are promising technologies which have potential in established (e.g. films, 
dressings and microparticles) and emerging scientific themes (e.g. nanomedicines and tissue 
engineering). Moreover, EHDA a one-step process facilitates us to optimise dosage forms as 
desirable in a single step for several age groups. 
The use of EHDA need to be more explored within the buccal research concern. It has shown 
great potential in this research concept; therefore, it is viable to pursue to wider area in this 
field.  
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Chapter 1 introduction  
 
1.1 Background 
 
The most important discipline of pharmacy is pharmaceutics which is related to the science of 
pharmaceutical formulation and drug delivery. Pharmaceutic scientists prepare an active 
pharmaceutical ingredient into a medication for patients use in a safe and effective manner 
(Platt et al., 2008). Over the past decades, considerable advances have been made through the 
science of drug delivery system and technology to pass the drug into the body (Zhang et al., 
2017; Yi and Kosel, 2017). Therefore, despite notable advances in the drug delivery system 
development, formulation and therapeutic agent and targeting to specific part of the body 
remain one of the most researched aspect within pharmaceutics. Lack of efficient drug at the 
site of action and body elimination of drug are the major drawbacks for drug delivery systems 
(Kiryukhin, 2014). During last decades there have been noteworthy growth in controlling the 
drug release of an active drug which is the key for drug efficacy. Drug targeting with specific 
drug delivery systems methods help to achieve optimal concentration range and as a result 
overcome toxicity of therapeutic and defence mechanisms of host. The development of 
targeting delivery (drug active in the target area) and releasing drug within period (sustain 
release) are the current efforts for drug delivery scientists. Moreover, many developments have 
been achieved to control the concept of pharmacokinetics, non-specific toxicity, 
pharmacodynamics, immunogenicity, bio-recognition and effectiveness of the delivery system. 
Therefore, understanding the combination of many factors such as polymer science and 
chemistry, biological system knowledge and pharmaceutics play part to develop the ideal 
delivery system (Mishra, Nayak and Dey, 2016; Debele, Mekuria and Tsai, 2016; Chahibi, 
2017). 
Parental and oral routes of administration were traditional choice as liquid or tablets; however, 
they also had many drawbacks subordinated with them. By utilising alternative routes of 
administration can overcome some of disadvantages (Gurruchaga et al., 2015). Medicines are 
administrated into the body by various routes of administration; such as enteral route (oral, 
sublingual and per rectum), parenteral route (intra muscular, intra venous...), inhalation and 
topicalto securely achieve its desired therapeutic effect. Each route has advantages, 
disadvantages and precise purpose. Route of administration is the major aspect of drug delivery 
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as it is responsible for drug accessibility and treatment (Moeller and Jorgensen, 2008; Prajapat 
et al., 2017). The route of administration and drug bioavailability are the most important factors 
in drug delivery. Therefore, the route for drug administration depends on the area of the body 
needed treatment, the way drug works in the body and the drug formulation.  
The release mechanisms for drugs are diffusion, degradation, and swelling. Furthermore, the 
drug delivery technologies amend drug release profile, distribution, absorption, and 
elimination, in addition to patient convenience and compliance. Drug release has been an 
important topic in pharmaceuticals and therefore there is a lot of determinations in such area to 
develop a targeted delivery in which the drug is only active in the target area of the body, 
sustained release formulations in which the drug is released over a period of time in a controlled 
manner from a formulation, and methods to increase survival of dosage which must pass 
through the stomach environment. Through the development in material design and 
engineering, novel materials with increasing complexity and more functions have been 
introduced into the development of drug delivery procedures and systems. 
 
1.2 Routes of Administration 
 
1.2.1 Enteral 
 
Enteral route comprises the drug travelling through human gastrointestinal tract. This route 
includes the stomach, oesophagus and the large and small intestine. The three enteral routes 
are Oral, Buccal & Sublingual, and Rectal. 
 
1.2.1.1 Oral 
 
The drug can be administered in different forms. It can be either liquids, tablets, capsules or 
chewable tablets. The drug typically pass through the mouth and the stomach and greatest 
amount of drug is absorbed in the small and large intestines. The drug then travels through 
the intestines and is delivered to the liver where it becomes metabolised, which limits the 
amount of drug that flows through the bloodstream and to the intended target site. When the 
drug is ingested orally other drugs and food in the GI tract can affect the rate of absorption of 
the drug. This route of administering the drug is the most convenient and usually the least 
expensive and that is why used the most. 
 3 
 
1.2.1.2 Sublingual and Buccal  
 
The dosage form can be placed between the teeth and gums (buccally) and under the tongue 
(sublingually) which can then be disintegrated or dissolved and then be absorbed into the 
blood stream through the small blood vessels which are situated under the tongue. The 
intended purpose of these forms is not to be swallowed. This route often gives a rapid 
absorption rate and can be rapidly enter the systemic circulation.  
 
1.2.1.3 Rectal 
 
Drugs that are given orally can be prepared and administered rectally as a suppository. The 
drugs are incorporated in a waxy material that liquefies or dissolves when it is placed in the 
rectum. Due to the rich blood supply and thin walls of the rectum the dug is readily absorbed. 
People who suffer from nausea when taking medication orally are often referred to taking 
suppositories instead to overcome this. 
 
1.2.2 Nasal 
 
A drug can be absorbed through the thin mucous membrane by breathing the formulation 
which leads to the nasal passages. To go through this route, the formulation should be 
transformed into atomised droplets in the air. The droplets are then absorbed through the 
nasal passages and then the bloodstream. Drugs moving through this way normally feel the 
therapeutic effects quite quickly. Some drugs used in this way can irritate the nasal passages. 
 
1.2.3 Inhalation 
 
The drug introduced to respiratory tract and which is containing of a complex selection of 
organs, tissues and cells. The drugs need to pass through the trachea and reach into the lungs. 
Depending on the particle size and shape, it determines how far the particles will travel in 
the lungs. Smaller particles usually travel further which increases the likelihood of the drug 
being absorbed in this area and enter the blood stream.  
It is likely that specialised equipment will be needed to assist to deliver the drugs through 
this route (Thomas, 2013). Generally, this way is for drugs that are specifically act on the 
lungs. 
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1.2.4 Parental 
 
Parenteral route is used by means of an injection through several routes: 
1.2.4.1 Subcutaneous (under the skin) 
 
The drug injected under the skin below dermis and epidermis, where the fatty tissues are, by 
injection. The drug then moves through capillaries and reaches the systemic circulation. 
However, there are not many blood vessels present in the subcutaneous area, therefore, it is 
usually used for slow or sustain drug absorption.  
 
1.2.4.2 Intramuscular 
 
Drugs given in large doses directly into the muscle. The absorption of drug is higher than 
subcutaneous tissue as there are larger and more blood vessels present in this area. The site of 
administration determines the volume of injection which is limited between 2 and 5 millilitres.  
 
1.2.4.3 Intravenous 
 
The drug is inserted directly into the vein using needle or tube as injection or infusion. This 
can be done as a single dose or continuous dose. An infusion is an example of a continuous 
dose and relies on gravity for it to be administered as well as infusion pumps which is pumped 
through flexible tubes known as a catheter. The purpose of this method is to avoid irritating 
solution which could cause discomfort intramuscularly and subcutaneously. It has been 
described to be the best to deliver a precise dose of medicine in a short amount of time and 
can be easily managed. This is the most continent in emergencies such as a stroke or 
poisoning. Furthermore, some drugs need to be given intravenously to avoid breaking them 
by enzymes in the stomach or liver.  
 
1.2.5 Topical 
 
Drugs are placed on the skin which is normally the area where the drug is needed to be active 
in and is used mainly on to treat superficial skin disorders, such as eczema, psoriasis and skin 
infections (fungal, bacterial and viral) as well as itchy and dry skin. The drug can be 
incorporated with different inactive substances into many different forms of topical 
formulation, such as a gel, solution, cream, ointment, lotion and powders. 
 5 
 
1.2.6 Vaginal 
 
Drugs in the form of a tablet, gel, solution, cream, suppository or ring can be given vaginally. 
The vaginal wall is the route where the drug can slowly absorb through. Oestrogen is usually 
given through this route to relieve vaginal symptoms such as, redness, dryness and soreness 
during menopause. 
 
1.2.7 Ocular 
 
Drugs can be incorporated with inactive substances to make a gel, liquid and ointment to treat 
eye disorders like conjunctivitis, glaucoma and injuries by applying them to the eye. The drug 
can be absorbed quickly through the eye if good and long contact before it runs off the eye. 
Prepared drugs in form of ointments and gels have a better retention time when being in contact 
with the eye as it remains in contact with the eye for a more significant time. Ointments and 
gels can commonly cause blurred vison.  
 
1.2.8 Transdermal 
 
Transdermal drug administration has been developed to overcome the problems that associated 
with the conventional formulation such as oral and parenteral.  It provides sustain and steady 
delivery through the skin into the blood circulation. Drugs can be prepared as a patch and be 
attached on most places on the body.  Formulation for these patches usually prepared with 
adhesive and enhancer and therefore help enhances the penetration of drugs through the skin 
into the bloodstream. The advantages of a patch would be slow drug release; therefore, a steady 
and continuous drug supply will be available for over a few hours to days and even longer. 
This allows for a constant level of drug in the blood. Drugs that are eliminated from the body 
quickly, patches are the best way to be delivered because if this drug was in any other form 
would have to be taken at regular intervals and frequently. On the other hand, patches can cause 
irritation to the skin. The drawback of this method of drug delivery is that the drug is really 
limited on how quick it can penetrate the skin and also it limited to small doses daily (Nair et 
al., 2018). 
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Table 1. 1 Routes of drug administration are described in the table below. 
Route Description  Advantages Disadvantages  
Enteral  Placement of drug directly 
into the stomach or 
intestine 
Economical, convenient First pass effect, drugs destruction by digestive 
liquids  
Buccal  Held inside the cheek 
(buccal area) 
Avoid first pass, rapid absorption, drug 
stability 
Inconvenience, dose limit, possibility of being 
swallowed, irritant drug can’t be given.  
Inhaled Breathed in to the longs   
Due to high surface area therefore, fast 
absorption  
 
 
Drug particle size and patient correct use of 
inhaler play part in bioavailability of the drugs 
 
Injection 
(intravenous, 
intrathecal, 
intramuscula
r and infused) 
Inject into the vein, muscle, 
or spine 
complete administered dose reaches the 
systemic circulation without delay 
 
Needs a utility equipment (e.g. cannula) 
Distressing especially for children 
Local reactions may appear by intravenous 
injections 
Rectal  Inserted into the rectum Excellent absorption, 
Hepatic first pass metabolism is avoided.  
Some patients do not like suppositories 
Oral  Swallowed by mouth 
(tablet, capsule, or liquid) 
Easy to use 
Favoured by patients 
Slow-release 
 
Not suitable for uncooperative patients 
Administered orally drugs usually absorbed 
slowly 
Stomach acid degradation and enzymes affect 
absorption 
 
Subcutaneous  Under skin injection Preferred for drugs with a low 
oral bioavailability 
Onset is faster than the above routes 
Can formulate to have very long duration 
of action 
 
Injections hurt, cause bruises and frighten 
children and needle phobic 
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Transdermal  Placed on the skin (e.g. 
patch) 
Avoids first pass and interference with 
gastric and intestinal fluids, once a day 
administration 
Possibility of local irritation, Drugs with 
hydrophilic structure having a low penetration 
through the skin, cannot achieve high drug level 
in blood 
Otic  Drops into the ear Less invasive, safe, and highly controlled 
system 
Anatomic obstruction of the window membrane, 
loss of medication, indistinct pharmacokinetic 
profiles. 
Ophthalmic  Eye drops, gel and 
ointment  
Easy to install, non-invasive, long contact 
time 
Blurred vision, 
Nasal  Into nose by spray or pump Drug first pass avoided, gastrointestinal 
tract fluid is avoided, rapid drug 
absorption, rapid onset of action,  
Relatively inconvenient, smaller absorption area 
compare to gastrointestinal tract. 
Topical  Applied on the skin  
Patient satisfaction 
Non-aggressive  
Easy to apply  
 
Absorption via skin is very slow especially for 
drugs with high molecular weight and poorly 
lipid soluble. 
 
 
 
Sublingual  Held under the tongue  Quick termination, first pass avoided, 
economical  
Large quantities not given, few drugs are 
absorbed, irritation of oral mucosa. 
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1.3 Drug delivery: Past, present, and future of medicine 
 
While conventional drug administration systems such as oral ingestions, eye drops, transdermal 
delivery and intravenous injections significantly impact on the control and treatment of 
diseases, but the on-going development of new administration route with better effectiveness 
and targeting biological therapeutic has direct and motivate scientists for development of smart 
therapeutic systems (Yi and Kosel, 2017).  
 
Figure 1. 1 Schematic map of human organs which interfere with drug bioavailability.  
 
Using specific carriers e.g. matrix materials were the one of the earliest progress in the drug 
delivery methods which aggravates release of active in spatial and time-based manner. This 
can be accomplished by having it as an implanted reservoir system or pulsatile fashion. 
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However, these methods are not without any drawback and many concerned such as specific 
target, bioavailability and intracellular need to be specified before any clinical commencements 
(Langer and Peppas, 2003). However, polymers proven that have vital part in moderating 
recent drug delivery systems. These systems give high therapeutic effects and play key role in 
newly drug delivery development which is not comparable with conventional dosage forms 
e.g. those which have been used for over the last four decades.  
 
Polymers play a big part in the manufacturing of pharmaceutics. Polymers action comprises of 
viscosity and flow modifying in liquid dosage forms and as binder in tablets. They are in use 
to improve the stability of drugs and used as film coating to mask the unpleasant taste of dosage 
form. Moreover, polymers help to modify drug release kinetics  
(Schwarzl et al., 2017). Application of polymer in drug delivery has been growing very fast 
and extended to very more complicated dosage form systems. As can be seen, that vaccine with 
polymeric micro particles has been developing to target specific area in the small intestine 
(Tawde et al., 2012). Adding to this, improvement and development of nano-size chitosan 
particles which could improve sustain release of promethazine which indicate encapsulation 
efficiencies of 99.7± 0.06% (Elwerfalli et al., 2015). Polymers in drug delivery has influence 
the transdermal drug delivery and rapidly growing as well. As in some formulation 
indomethacin has been combined into conductive polymer (polycarbazole) film. This enhance 
drug penetration control and modulation through influencing cross-linking ratio and an external 
electric field; giving rise to a firm controlled transdermal patch system (Thorngkham et al., 
2015). 
 
As polymer application and the development continue, for specific target the type of polymer 
become more vital especially for some delivery systems functionality and structural property 
is important to be concerned. Polymers are either synthetic or natural. Natural polymers are 
attained from freely existing sources, which are typically water based and can be extracted e.g. 
cellulose, agar, chitosan, collagen, silk, DNA, and other proteins.  But synthetic polymers are 
attained form petroleum oil and consequently modified by chemical methods. Examples of 
synthetic polymers are as polylactic-co-glycolic acid (PLGA), polycaprolactone (PCL), 
polylactic acid (PLA) andpolyvinylpyrolidone (PVP) polyethylene (PE), and polyester. There 
have been many developments in biodegradable synthetic polymeric recently which direct into 
development of e.g. polyglycolide (PGA), PLA, PLGA, and polydioxanone (PDA)). These 
new inline synthetic polymers shown an ideal member for drug delivery family and validate 
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acceptable in vivo and in vitro properties (Gajendiran et al., 2017). Overall, all polymeric 
biomaterials which are used in drug delivery are endangered to be inspection and effected by 
surrounding hot environment. In several cases, the reliability of the polymer for intended use 
has been compromised due to biodegradation. Adding to this, it is extremely important to allow 
non-toxic removal of the material. As a result, natural polymers (e.g. collagen, gelatine, 
hyaluronic acid, elastin, aginate, chitosan, heparin, chitin and chondroitin) became more 
favourable and frequently used for different aspect such as healing the wounds and burn and 
also developing renewing medicine applications (Sensharma et al., 2017; Murdock and 
Badylak, 2017; Gajendiran et al., 2017). 
However, synthetic materials such as PLA, PLGA and PCL also possess very similar properties 
which have driven their utility in numerous drug delivery and biomaterial applications 
(Sensharma et al., 2017).  
 
1.4 Buccal delivery  
 
The development of new drug involves high amount of cost including money and time 
therefore, it is essential for pharmaceutical industry to reassess delivery option to improve the 
drug efficacy that have already been accepted. On the other hand, oral delivery is the preferred 
route for drug administration due to low cost, patient compliance and easy to administrate. But, 
the degradation of some drugs such as peptide and proteins from gastrointestinal (GI) and 
hepatic first pass metabolism barriers limits the administration (P. M. Castro et al., 2015). As 
a result, mucosa was considered as promising site of interest for drug delivery. These include 
oral cavity, ocular, vaginal, rectal, nasal, and mucosal lining. Amongst these, due to 
physiological feathers and patient compliance, oral cavity attracts consideration for drug 
administration (Deepak, Goyal and Rath, 2018; Jug et al., 2018; Lai et al., 2018).  
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Figure 1. 2 Schematic mouth lining mucosa (top) and schematic diagram of buccal mucosa 
(bottom) (Patel, Liu and Brown, 2011) 
 12 
 
 
Because of rich vascularisation of oral mucosa and high permeability to very much of drugs, 
buccal route become an important route of drug administration as an attractive alternative to 
the oral and parenteral routes for systemic drug delivery (P. Castro et al., 2016; P. M. Castro 
et al., 2018; Morantes et al., 2017; Mahmoud et al., 2018). It has high total blood flow which 
ensures systematic bioavailability, helps overcome early drug degradation due to pH and 
enzyme activity of the gastrointestinal tract (GT), avoids active drug loss due to first-pass 
hepatic metabolism (Fonseca-Santos and Chorilli, 2018). Therefore, it is essential for the 
improvement of the therapeutic benefit of many formulations (Russo et al., 2016; Nafee et al., 
2003).  
Buccal administration route is an alternative to oral route. The buccal drug delivery permits the 
drug to be delivered across the oral mucous membrane through a passive diffusion process 
where the drug enters the blood stream directly through oral cavity (P. M. Castro et al., 2018). 
Buccal drug delivery can improve the absorption of many formulations by avoiding specific 
problems associated with the drug such as low absorption, decomposition, gastro intestinal 
irritation, pH problems, due to first pass metabolism in the liver after absorption to the 
bloodstream and short half-life frequent dosing (Fonseca-Santos and Chorilli, 2018).  
It is suitable to be used for treatment of diseases in which prolong release of drug is needed.  
Also, drugs which cannot be administrated through oral route due to their poor absorption, 
degradation or high molecule weight, are of interest to be used in buccal route (P. Castro et al., 
2016). Preparation of appropriate excipient for the buccal delivery systems could give us a non-
irritant and safe dosage in the mouth with sustained-release. However, the main disadvantages 
of this route are comparatively small surface area of oral mucosa, uncontrolled swallowing and 
salivary flow and consequently loss of drug. Therefore, the challenge for the success of buccal 
release is the residence time and maintain dosage contact with the membrane of the dosage 
forms in the buccal environment which allow the drug act at the buccal site.  
A buccal area is the inside of the cheek, plus an area between gums and upper and lower lips 
(Kraan et al., 2014). Buccal delivery system can be used for either topical or systemic drug 
delivery. Buccal lining is 500-800 µm in thickness and covers 1/3 (100cm2) of total oral cavity 
surface (Sattar, Sayed and Lane, 2014; Fonseca-Santos and Chorilli, 2018). Oral cavity 
epithelial mucosa differs according to tissue function and is a barrier to lipophilic drugs. 
Submandibular, sublingual and parotid glands produce saliva liquid. Saliva is distributed over 
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the mouth and cover the epithelial cells. Saliva comprises of mucus, enzymes, proteins and 
minerals (Hannig et al., 2017; Fonseca-Santos and Chorilli, 2018; Malallah et al., 2018).  
Buccal mucosa has been widely explored recently, though, its potential as drug delivery route 
has been known for centuries. Nowadays researchers coming up with novel drug delivery 
systems to provide better bioavailability and convivences, such as films, patches, adhesive 
tablets and nanotechnology-based systems. 
Transcellular and paracellular are the major drug transport across buccal mucosa (Abd-Elbary 
et al., 2016). It has a rich blood supply which facilitates the direct entry of drug molecules into 
the circulation system and therefore improves the bioavailability of drugs (Ansari, Sadarani 
and Majumdar, 2018).  
It is important that the excipient (polymer) has the ability requirement for buccal administration 
which is optimal polarity and fluidity. This is to make sure the polymer is sufficiently wetted 
by the mucus and to consents common adsorption and the action of penetration between 
polymer and mucus to take place within a realistic time schedule (Ikeuchi-Takahashi, Sasatsu 
and Onishi, 2013).  
Because buccal has a superb accessibility of the absorption area, toughness, and the prospects 
of high patient acceptance, and permits drug absorption to be terminated in the case of any 
adverse reaction will direct to a regular attention to this area for drug delivery (Nazari et al., 
2017). The best buccal dosage form must have the following prospects. It should a) stay in its 
position in the mouth for intended hours b) drug release should be in controlled manner c) 
unidirectional drug release toward the mucosa.  
Therefore, to achieve these requirements for a buccal dosage using right mucoadhesive 
polymers as excipient is important. The mucoadhesive should be able to control drug release 
as well. (Govindasamy, Kesavan and Narasimha, 2013) 
 
1.5 Processing Technologies 
 
Due to favourable physical properties such as lower density, ease of modification, measured 
degradability and minor environmental effects, polymers gained attention in pharmaceutical 
field (Vedadghavami et al., 2017). The new development in drug delivery systems are as result 
of advances that gained from polymer science. The need for new and more effective 
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biomaterials has helped for development of various polymers, especially during the last 
decades. The development cost and property of the biomedical are the important aspect for 
manufacturing and the development of delivery systems. Process-ability, impact strength, 
biodegradability and biocompatibility are other aspect to be considered for biomedical 
applications. Furthermore, the biomedical need to be processed and explored by several 
technologies such as spray drying, microfluidics, super critical fluids, soft lithography and 
freeze drying. This allows designing, analysing and controlling the process parameters and 
manufacturing protocols and aiming at understanding the materials by monitoring them in a 
timely manner and therefore reducing the process time and enhancing consistency and the 
quality of final product. This is important as choosing and designing the right polymer for the 
right technology is a challenging task.  Desire polymer should have mechanical, interfacial, 
chemical and biological function of purpose of use (Pillai and Panchagnula, 2001).  
 
1.6 Spray drying 
 
Spray drying is a continues process of drying solutions, suspensions and liquids. It is a simple, 
rapid, easily scalable and reproducible technology which is well accepted in industry (Sarrate 
et al., 2015), (Paudel et al., 2013). It is a constructive one step process that compromises the 
transformation of a material from a uniform solution or suspension state into a fine dry powder 
particle. This achieved from atomisation through a nozzle into a hot drying gas medium 
(Seremeta et al., 2014). The formulation loses moisture quickly and dry when encounter with 
stream of hot gas. By changing the parameters for example formulation viscosity, rate of 
feeding or atomization pressure, it is conceivable to modify the produced particle size (Hede, 
Bach and Jensen, 2008). In addition, the final product (powder) produced have practically 
consistent characteristic (Davis and Walker, 2018) and (Davis and Walker, 2018). There has 
been such a development and improving in all parameters of this technology. These include air 
dispenser, air inlet control, temperature and energy optimisation spatially for sensitive drugs, 
and overall the sanitary aspects of the complete system. Further system control could be 
developed and adjusted for inline and online control and measuring the final product quality. 
Spray drying provides advantage of incorporating several excipients into one formulation and 
many of parameters can be adjusted to produce and design the powder for intended use for 
instance powder for lungs delivery. This system was used for numerous drug delivery 
development systems and used for preparation of several pharmaceutical products such as 
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tablets, microencapsulated ingredients and respirable powders. This method of drying is 
favourable not only because of producing consistent particle size and morphology but also 
preparing many heat sensitive materials.  
This method used for the encapsulation of didanosine (water-soluble anti-retroviral used in the 
treatment of HIV) as for the biocompatible synthetic PCL which produce particles with range 
diameter size of about 36-118 µm and encapsulation efficiencies ranging from about 60-100% 
(Seremeta et al., 2014; Sosnik and Seremeta, 2015). 
 
1.7 Microfluidics process 
 
Microfluidic processes and capabilities are multidisciplinary field where small amount of fluids 
are mixed, separated and moved forward and therefore, accurately controlled and handled in 
channel of between 10-100 nanometres. These technologies employ several cooperative micro-
engineered platform technologies which incorporate with micro-channels, micro-membranes, 
modiﬁed surfaces and immiscible liquids at accurate interfaces. A typical microfluidic set up 
includes syringe pump, and tubing which connected to a microfluidic device. The device 
usually residences on top of a microscope slide.  
In the field of drug delivery, the microfluidic technique can fabricate monodisperse 
nanoparticles with uniform morphology and size, which is a great advantage compare to other 
method of nanoparticle preparation (Zhao et al., 2017; Costa et al., 2017; Balbino et al., 2017). 
The key benefits of microfluidic systems rotate around implementing operation systems that 
can be used to require for a laboratory in a micro size device that can be reproducible and 
controlled. Particles obtained from microfluidic devices display little polydispersity. Moving 
away from conventional types of microfluidics (i.e. for the preparation of near uniform particles 
or droplets, when two immiscible liquids meet at micro-interfaces) (Björnmalm, Yan and 
Caruso, 2014), several other therapeutic forms have emerged from microfluidic principles. 
Recent developments have shown microfluidic engineering of drug particle eluting 
microbubbles and drug particle generating droplets (Kucuk et al., 2014). However, the scale of 
operation usually becomes a bottle neck for such systems. A variety of microfluidic devices 
have also been explored for other biomedical applications, which enable on-chip point of care 
diagnosis as well as real time monitoring using minute quantities of body fluid [.For example, 
biomarker detection in disease diagnosis for cancer, in comparatively rapid fashion, has been 
demonstrated (Y. Wu et al., 2014). 
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Figure 1. 3 Simple two unite gravity driven microfluidic system: a) scheme of microfluidic 
system setup; b) image of overflow system; c) closeup image of the overflow bottle. (Gao et 
al., 2019) 
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1.8 Supercritical fluids (SCF) 
 
Engendering of particles in drug delivery which gain control of particle size and polymorphic 
purity can be challenging. Particle size is important by means of it is affects the path of drug 
delivery and as a result the targeted area. Ideal particle size for intervenors delivery should be 
around 0.1-0.3 µm. for inhalation delivery 1-5µm. and for oral delivery 0.1-100 µm. regardless 
of these facts, control and modifying the particle size  cannot always be achieved by the 
conventional micronizing such as milling and grinding or jet milling techniques which does 
not produce uniform particle size distribution (Tabernero, Martín del Valle and Galán, 2012).  
Supercritical fluid technique has been employed for the formation of verity particle sizes. It 
has been used to produce ultrafine particle and has great advantages over conventional size 
reduction methods. The process based on the solvent-impact phase separation in which the 
addition of gas causes the precipitation of particles (Yeo, Choi and Lee, 2000; Reverchon, 
1999). 
 Another alternative strategy in polymer process engineering technology is the supercritical 
fluid technique that is classified for crystal and particle engineering for developing cosmetic, 
drug delivery and pharmaceutical materials (design of particles, particle size control or 
polymorphic purity) for which it has shown great promise. Supercritical fluids are liquids and 
gases deployed at pressures and temperatures above their critical points (Figure 1. 4). At critical 
point the change in volume between the two phases goes to zero and above the critical point 
there are no longer noticeably defined phases. Therefore, this means that a supercritical fluid 
cannot be compressed with decreasing volume and increasing pressure into liquid at constant 
temperature. Also, a supercritical fluid will not evaporate to vapor by reducing the pressure 
and increasing volume.  
 
Figure 1. 4 Phase diagram of physicochemical properties of a compound. 
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This process can be driven using a selection of materials and co-process which give rise to 
particle size control engineering. The sub-processes developed here can involve rapid 
expansion, re-crystallisation, solvent extraction and gas saturated suspensions, with resulting 
particle size ranging from a few hundred nanometres to several hundred microns(Yeo, Choi 
and Lee, 2000; Montes et al., 2016; Djerafi et al., 2017).These methods have been favourable 
due to their green (environmentally favourable) nature. 
 
1.9 Soft Lithography 
 
Over the past years, microfabrication technology has gained great interest and development for 
variety of health care related products. A lot of research is done on diagnostic tools and 
microdevices for therapeutic applications such as implants and drug delivery micropumps.  
Microparticles made of silicon dioxide and photocurable polymers have been generated using 
the photolithography microfabrication technique. In this instance microparticles demonstrating 
low polydispersity and similar surface chemistries were prepared for deployment as drug 
delivery systems. Nevertheless, there is a limited choice of materials, and in addition some 
lithographic fabrication method requirements include the utilisation of corrosive etching 
solutions which may damage delicate or sensitive compounds (Tao and Desai, 2003; Hilt and 
Peppas, 2005). Micro- and nano-fabrication using an elastomeric stamp, which is prepared by 
cast molding based on self-assembly and replica (to generate pattern and structures with mean 
sizes ranging from ~30 nm to 100 µm) is a general method of several non-photolithographic 
techniques which are termed ‘soft’ lithography. In comparison to non-photolithographic 
processes, planar and non-planar surfaces as well as 2D and 3D structures can be generated. 
This can be demonstrated as; microcontact printing (µCP), replica molding (REM), solvent-
assisted micromolding (SAMIM), micro-transfermolding (µTM) and micromolding in 
capillaries (MIMIC). Moga et al. (2013) demonstrated the direct fabrication of biocompatible 
dissolvable polymeric microneedles on to water soluble substrates (flexible) through a soft 
lithography method (PRINT - particle replication in non-wetting templates) presenting the 
ability to penetrate both murine and human skin samples. Polymeric microneedles were 
prepared from biocompatible and water-soluble polymer, PVP (10 kDa) and rhodamine B dye 
at a loading concentration of 0.1%. Here, rhodamine B dye was clearly delivered to both 
selected tissue types (ex vivo murine and human skin specimens). Hence, the conclusion stated 
that such polymeric micro-needle patches can be used to prevent or treat a variety of systemic 
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and local diseases, including skin cancers, vaccines and other treatments that need routine 
hypodermic type of injections. 
 
1.10 Spray Freeze-Drying 
 
Spray freeze drying characterised by atomisation of the suspension or solution into the cold gas 
phase of the evaporation cryogen. During the proses the porous flow chamber is cooled down 
to the desired temperature usually lower than -50°C using liquid nitrogen. After that liquid feed 
is atomised into the cryogenic gas within the flow chamber. The result frozen droplets are 
collected on the exit filter at the bottom. Solidification of droplet starts while passing through 
the refrigerant vapor above the liquid surface. After that the microscopic droplets which were 
freeze in the cold air are fluidised inside the chamber until all the moisture has been removed 
by sublimation under pressure and low temperature (Teixeira et al., 2017; Wanning, Süverkrüp 
and Lamprecht, 2015). Spray freeze-drying techniques have been developed to avoid high 
temperature usually associated with other pharmaceutical engineering methods such as spray 
drying, as this can be damaging to polymeric excipients and the active ingredient. 
Microencapsulation of proteins in biodegradable polymers is a viable route for their delivery 
and sustained release which has been demonstrated on the micron scale (Adeli, 2017; Borges 
Sebastião, Robinson and Alexeenko, 2017). Recently, the spray freeze-drying method has been 
explored as an alternative to the ionic gelation technique for the generation of chitosan and 
alginate nanoparticles intended for colonic delivery. In this instance, nanoparticles containing 
prednisolone and inulin were developed using two separate processes; spray freeze drying 
using chitosan and spray freeze drying using alginate. Characterisation and assessment of 
nanoparticles was based on release kinetics of prednisolone and inulin, sensitivity to lysozyme 
degradation and bacterial and faecal slurry stability. The findings indicate chitosan 
nanoparticles demonstrated similar particle sizes and structures but with lower encapsulation 
efficiency for inulin. Moreover, less degradability in the presence of lysozyme and E. coli and 
no degradability by faecal slurry were also shown. In contrast, alginate loaded nanoparticles 
displayed appreciative encapsulation parameters for both actives, and biological degradability 
by E. coli and faecal slurry was also confirmed (Gamboa et al., 2015; Wanning, Süverkrüp and 
Lamprecht, 2015).   
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1.11 Electrohydrodynamic Atomization (EHDA) Technologies 
 
EHDA is a process by which electrical forces are used to atomise liquids. Appling voltage 
which is the driving force, solution formulation is force out of the nozzle, therefore, producing 
the formulation as micro/nano fibre or particles depending on the formulations. These 
structures are currently attracting a lot of interest in the biomedical field, applicable to an 
extensive range of applications (i.e. drug delivery and biomaterials).  
 
 
Figure 1. 5 Schematic electrospraying setup 
 
In this engineering technique, small droplets are obtained from an electrically forced (electro) 
break-up of a moving (dynamic) liquid (hydro) at a controlled flow rate through a conducting 
capillary needle (or nozzle) maintained at several kilovolts (usually ~30 kV max) relative to a 
ground electrode. The EHDA process is a well-known yet maturing physical process where a 
liquid jet (such as drug formulation) breaks up into very small droplets due to electrical and 
mechanical forces. This is dependent on the strength of the electrical stress and the resulting 
kinetic energy of liquid jet leaving the nozzle, which contribute towards a variety of spraying 
(or jetting) modes. Once these droplets are ejected, the base solvent in the liquid formulation 
evaporates leaving behind, typically, polymeric excipients and drug to form solidified matrix 
systems on nanometre scales. The formulation or processing liquid in this regard is optimised 
to engineer surface and dimensional properties of dried structures.  
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Basic EHDA principles (interacting antagonistic forces during EHDA jet enablement) are 
usually coupled with formulation material properties (visco-elastic properties) which are often 
utilised to determine process viability, fibre or particle generation and size of structures. For 
these reasons, the deployment of polymeric materials (both natural and synthetic) in these 
processes has been very favourable; to engineer a range of micron scaled drug delivery systems. 
Several formats of the EHDA processes exist, including electrospinning (for fibre and thread 
generation), electrospraying (for particle or droplet formation), multiple needle coaxial forming 
(layered particles and fibres), bubbling (gaseous vesicles) and more recently printing and 
patterning (ordered architectures). When voltage is applied to the conducting needle, the 
flowing liquid (formulation for drug delivery) forms a jet at the needle orifice, which breaks 
up into fine droplets that are electrically charged, therefore enabling them to be guided and 
focused easily, minimising droplet agglomeration. This technique also allows the generation 
of near uniform size distributions (once optimised) along with ambient temperature processing, 
which are distinct advantages when compared to existing pharmaceutical technologies not 
viable for sensitive materials (e.g. proteins and peptides).  
It was William Gilbert in 1600 who observed and record this spectacle. Following observation 
on electrospraying was by Jean-Antoine Nollet in 1750. But it was in 1900 when the first 
patented EHDA setup was recorded. Rayleigh made the earliest observations on droplet 
instability due to electric charges and suggested the conditions for a drop or jet to become 
unstable, since the stability of the drop or jet is dependent on the balance of forces, i.e. the 
outward electrical stresses disrupting the drop and the counteracting surface tension forces 
trying to hold the droplet together. Based on Rayleigh’s theories, Zeleny pioneered early 
experimental studies of EHDA and observed different modes of spraying at the exit of a 
capillary, which was exposed to an external electric field; able to produce a qualitative 
description of the process based on specific parameters (flow rate and applied voltage) (Xie et 
al., 2015).  
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Figure 1. 6 Schematic of droplet in presence of electric field 
 
 
Figure 1. 7 Spraying modes, A and B) droplet, C) shows Tyler cone, D) single jet, E) double 
jets, F) multi jets 
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Since the late 20th - early 21st centuries this phenomenon has attracted a considerable amount 
of interest from both fundamental and application viewpoints, and experimental features in the 
apparatus used by Zeleny are still being used and developed further by scientists. The 
production of droplets during electrostatic atomisation can be detected because of applying an 
electric potential difference between a ground electrode and the conducting capillary/nozzle 
(used for formulation media flow).  Based on the balance of the competing interaction between 
the electrical force and surface tension, the jet formed from the capillary can break up into 
droplets in several different ways. Many researchers have discussed the various modes of 
electrostatic atomization and have classified them according to the properties of meniscus and 
jet. Most researchers have used the geometrical forms of the jet and meniscus as defining 
conditions of process viability (Grace and Marijnissen, 1994). These modes are discussed 
based on two main characteristics; 1-the geometrical configuration of liquid orientated at the 
capillary needle exit, and 2-the type of jet formation and subsequent disintegration into droplets 
according to the studies by Jaworek and Krupa (1999) (Jaworek and Krupa, 1999). Based on 
these criteria, the spraying modes are divided into two groups. The modes in which liquid 
fragments are ejected from the capillary exit (e.g. dripping and spindle modes) and the modes 
in which the liquid produces a continuous jet, which subsequently breaks up into droplets a few 
millimetres from the exit of the capillary. The second group (meniscus and the jet) can be 
stable, vibrating or rotating in a spiral fashion circulating the capillary; an example is the 
famous desirable cone jet mode (stable).  
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Figure 1. 8 Image of electrospinning needles. A and B) single needle with different diameter, 
C and D) Coaxial needles system and E) Schematic of coaxial needles system. 
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Figure 1. 9 Image of electrospinning products. A) Fibres dispensed on collector surface, B 
and C) fibres cuts.  
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1.12 Processing parameters 
 
The key variable in establishing the cone-jet mode is the applied voltage, and the cone-jet mode 
can prevail within a range of applied voltage values, permitting the establishment of an 
operating window for stable jetting. The electric field is a key parameter in controlling the 
process and is dependent on the distance between the needle and the ground electrode. A greater 
applied voltage leads to a stronger atomisation effect on the liquid (or formulation), which is 
mainly due to electrical forces produced by this field. At a desirable specific voltage range, the 
meniscus of liquid becomes conical and stationary and below this the liquid ejection at the 
nozzle/needle often operates in pulsating mode. Droplet size reduces with an increase in 
applied voltage and increases with the flow rate, thus it is paramount to select the highest 
possible value of applied voltage and the lowest possible value of flow rate to achieve the 
minimum droplet size which correlates to particle diameter once dried. However, the influence 
of the applied voltage in the EHDA description of a liquid is relatively small when compared 
with the flow rate, i.e. for highly conducting and viscous liquids the size of electrosprayed 
droplets from the cone-jet mode are relatively insensitive to the applied electrical field.  
 
A stable cone-jet mode does not exist below the minimum flow rate of every single liquid, as 
each liquid has a minimum flow rate for EHDA processing. The size distribution generated in 
EHDA (cone-jet mode) depends on several factors and these include the diameter of the jet, 
and its resulting break into miniaturised droplets. The process of jet breaks up is mainly due to 
varicose instabilities at the minimum flow rate. At higher flow rates the charge on the jet 
surface increases. Above a certain surface charge value, the lateral instabilities of the jet also 
come into play and are often termed kink instabilities. The size distribution of main ejected 
droplets also becomes wider based on the magnitude of these instabilities. The minimum flow 
rate (Qº) of a liquid sprayed in the cone-jet mode can be estimated by using the equation 
provided by Ganon-Calvo (1997):  
 
                                                              
 Qº = ε° /Kρ Equation 1. 1 
 
Where ε°, K and ρ are permittivity of free space, electrical conductivity and density of the 
liquid, respectively. The flow rate influences the droplet size and fabrication rate extensively 
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and it can be adjusted by varying the output of the syringe pump or by changing the cross-
sectional area of the tube transporting the liquid. Only within a certain flow rate range does the 
cone-jet mode form and these limits are generally imposed experimentally. The EHDA process 
is not stable if the flow rate is considerably low as the liquid volume is not enough to form the 
cone shape and here the liquid relaxes to form a droplet shape intermittently. Conversely, if the 
flow rate is increased above a critical value, the impact on droplet size distribution becomes 
strikingly apparent which yields more polydisperse structures. The process becomes more 
unstable with increasing flow rate and as a result the polydispersity increases. 
 
Additionally, there are a few more parameters that need to be considered such as the 
configuration of the needle, the ground electrode (including its shape and movement) and the 
wettability of the needle. The shape/geometry/movement of the ground electrode (point, ring 
or plate) can determine the deposition behaviour of resulting droplets, andplays a crucial role 
(especially with regards to newer technologies involving patterning) in the EHDA process. 
Also the distance between the needle tip and the ground electrode affects the EHDA process; 
when the ‘’needle exit to ground’’ spacing is large, the applied voltage boundaries for the 
various stability parameters are higher. 
Figure 1 provides images of typical laboratory set-up of an EHDA system showing (a) key 
components, (b) spraying during the cone-jet mode, (c) spinning of fibres from an electrically 
conductive nozzle and (d) a close-up of coaxial EHDA needles. To demonstrate these processes 
PVP polymer-dye-ethanol formulations were used. 
 
1.13 Advantages and disadvantages of electrospinning process 
Numerous methods have been used to manufacture drugs in pharmaceutical manufacturing for 
different propose such as quality and to lowering the cost of manufacturing. Electrospinning is 
regarded as a versatile and simple method to generate ultrafine fibres that are between tens of 
nanometres and several micrometres in diameter using a rich variety of materials that includes 
polymers, inorganic materials, and composite materials. It is worth noting that electrospinning 
is a continuous process that results in the formation of longer fibres compared to fibres prepared 
by other chemical or physical methods. Homogeneous morphologies and structures can 
produce desired properties by controlling the process parameters and/or designing special 
electrospinning apparatus. 
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Electrospinning presently has numerous restrictions. First the variety of polymers used in 
electrospinning is limited. Second, electrospinning has been implemented at industrial level; 
however, in terms of producing fibres for the application of filters electrospinning is inferior to 
traditional methods due to its higher cost to produce fibres with large diameter. In addition, the 
disadvantages of high cost of production, process controlling make electrospinning more 
attractive. 
Synthetic and naturally occurring polymers have been utilised in both well established and 
emerging pharmaceutical (and therapeutic) materials and dosage forms. The utilisation of these 
materials has also been expanded from serving as mere fillers and single function matrix 
materials to controlled release excipients and multi-functional enabling structures. The latter 
has been expedited due to further functionalisation or careful engineering. EHDA technologies 
are robust technological platforms permitted the one-step engineering of a selection of 
polymers (and therefore integration of their unique properties) on several scales which are able 
to meet requirements from the past and those currently emerging as future therapies including 
fibres, nanoparticles and bubbles.  
 
1.14 Process analytical technologies 
 
An optimised electrospinning/electrospraying (EHDA) process can be considered as that which 
achieves an optimised drug product for the least cost (include time and money). This requires 
an understanding of the factors affecting each of the controllable parameters in the EHDA 
process. There is therefore increasing interest in the deployment of reliable, and rapid feed-
back technology to aid in the EDHA process control. This could minimise the development 
time through enhanced understanding of the material attributes of the product and the process 
parameters required for an optimised process. From this understanding one can develop a 
control space that will ensure that the product meets its target quality product profile.  
Monitoring of the control space requires in line QBD tools; process analytical technologies 
(PAT) which provide feedback control of various critical to quality attributes of the product, 
such as final fiver diameter size or particle size content. 
Process analytical technology (PAT) is an organization for designing, analysing, and 
controlling manufacturing productions. This is done all the way through a well-timed 
measurement (e.g. during processing) of essential quality and performance attributes materials 
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and processes with the aim of ensuring final product quality (Yu et al., 2004). The desired aim 
of the PAT framework is to design and develop processes that can consistently ensure a 
predefined quality at the end of the manufacturing process. 
In the EHDA area there have been many developments in process analytical technologies to 
control different aspect of the process (e.g. Tyler cone, jetting, spray and fiber/particle size). 
These are frequently classified as individual online measurements, which include technologies 
such as high definition camera, laser particle size measurement, live monitoring of the process. 
 
1.15 Limitations of currently available process analytical 
technologies 
 
Most of the process analytical technologies are intended for the determination of end of 
process. Implementation of new technology is needed to the system which could help for 
optimising the process parameters and as result impact product homogeneity. Moreover, 
equipment set up, the environment and the electrospinning system itself play part in the final 
production and end-product results. However, system in en-closed system can have better 
result.   
 
1.16 Material/Physical properties 
 
The main material/physical properties of liquid (formulation) which influence the EHDA 
process are viscosity, surface tension, relative permittivity, electrical conductivity and density. 
Viscosity is a fundamental liquid property playing a significant role in the jet break-up process 
by influencing the hydrodynamic aspect of EHDA modes, which also impacts on the size of 
generated droplets, thus the resulting particles after drying. In the EHDA process, an increase 
in viscosity over three orders of magnitude has a dramatic effect on the size of particles 
obtained that also leads to an increase in droplet size. Rosell-Llompart &de la Mora (1994) 
suggested the effect of solution or medium viscosity on resulting droplet size is dependent on 
a dimensionless parameter πη in the cone-jet mode, given by:  
 
 
 πη =
( √𝛾2
3
𝜌𝛽𝜀°/𝐾)
𝜂
⁄   
Equation 1. 2 
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Where η, γ and ρ are the viscosity, surface tension and density of the liquid respectively, and 
β, ε° and K are the relative permittivity, vacuum permittivity and electrical conductivity of the 
liquid respectively. They proposed that if πη is >> 1, the viscosity of the perfused liquid has no 
impact on the resulting droplet formation, but if πη<< 1, the droplet size correlates with solution 
viscosity and also, a broader droplet size distribution will result [41]. The surface tension of 
liquid formulation also has considerable effect on atomisation; if the surface tension is 
increased, an increase in electric field is then essential to attain the desirable EHDA mode(s). 
The necessary applied voltage for stable cone-jet mode will increase with the liquid surface 
tension as shown in the work conducted by Smith (1986). Also, the atomisation of a liquid is 
difficult if its surface tension is above ~50 mNm-1 (Smith, 1986; Kaiser, Kaiser and Weeks, 
1993; David, 1986). However, other studies have indicated that droplet size is independent of 
the surface tension of liquid. 
The relative permittivity is the ability of a material to be polarised in response to an applied 
electric field. Polarisation reduces the electric field within a liquid. Therefore, the relative 
permittivity will resist the formation of an electric field within a liquid and further affect the 
time taken for the charge to reach the liquid cone. Relative permittivity along with the vacuum 
permittivity and conductivity determines the electrical relaxation time, which is the time 
needed to level perturbation in the electric charge. 
The most important material/physical property for electrospraying in cone-jet (stable) mode is 
the liquid (or formulation) electrical conductivity. In contrast, if the electrical conductivity is 
too high, EHDA processing will be impossible due to coronal discharge which impacts the 
stable cone-jet mode. Liquids which have low electrical conductivities (insulators) cannot be 
subjected to EHDA processing (e.g. olive oil), even if they can be electrosprayed in cone-jet 
mode through superficially increasing their conductivities with additives or excipients such as 
ethanol [43]. According to experimental results obtained by Smith (1986), the lowest limitation 
of conductivity is 10-11 Sm-1. Furthermore, it was found that conductivity had a distinct effect 
on the morphology of liquid deformation at the nozzle exit during the EHDA process. The jet 
diameter, jet length, droplet size and flow rate in cone-jet mode all decreased distinctly as the 
electrical conductivity was increased. 
 
The density of the liquid plays a role in determining the jet diameter in the cone-jet mode. Once 
the viscosity and electrical conductivity of the liquid formulation are sufficient, the electrical 
charge is efficiently transmitted across the jet section by viscous forces. However, the viscous 
force depends on the density of the liquid. At the cone base, the liquid density is of some 
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importance due to the influence of gravity on the cone shape, although the acceleration of the 
liquid does not play an important role and is very small. For large capillaries (>1mm), 
gravitational forces influence the shape of the cone.  
 
1.17 EHDA Spraying (Electrospraying) 
 
Electrospraying is emerging as a widely acceptable method for forming polymeric micro- and 
nano-scaled structures via liquid atomisation. The diameter of resulting electrosprayed droplets 
range from hundreds of microns down to tens of nanometres. The size distribution of droplets 
can be near mono-disperse. The generation of droplets and their size can be varied by 
manipulating the flow rate of the liquid formulation and the applied voltage at the conductive 
capillary needle. The ejected droplets are electrically charged and this facilitates their motion 
or deposition on to desired substrates. Electrospraying has been utilised extensively for the 
encapsulation of therapeutic agents particularly within biodegradable and biocompatible 
polymeric particles (on the nanometre and micrometre scale. The concepts have also been 
applied to other existing microstructures which have potentials as dosage forms. For production 
of near uniform sized particles, the cone-jet mode is the most appropriate and popular EHDA 
jetting mode. In addition to permitting facile particle size control during process engineering, 
the ambient nature of the electrospraying technique also limits damage to sensitive 
pharmaceutical agents. For example, Gulfam et al. (2012) have electrosprayed nanoparticles 
from natural occurring gliadin polymer for the controlled release of anticancer drug 
cyclophosphamide; with particles displaying average diameters of 218.66 ± 5.1 nm, 
demonstrating a narrow size distribution and gradual drug release over 48 hrs. Furthermore, by 
incorporating gelatine into the existing polymeric matrix system, the release kinetics of the 
drug was enhanced by expedited delivery of active. This clearly demonstrated the valuable 
nature of matrix material composition and facile engineering via the electrospray process to 
develop tailor made controlled release nano products as chemotherapies. Cyclophosphamide is 
a cyclic phosphamide ester of mechlorethamine, which is used in the treatment of 
neuroblastoma, breast cancer, retinoblastoma and lung cancer viacross-linking with DNA 
which prevents cell division. The electrospraying of silk sericin/alginate systems has also been 
demonstrated (264-284 µm) but in this instance was focused on the delivery of silk sericin, 
which in recent times has demonstrated interesting biological properties such as an antioxidant 
and as a bio-adhesive material. The encapsulation of the active was above 80% and was 
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released in controlled fashion. BSA, a model protein, has also been used to coat, via 
electrospraying, comparatively coarser lactose particles which are used in numerous 
pharmaceutical applications. Unlike conventional ‘spray’ type coatings which spread during 
coalescence, BSA particles (spherical, ~700 nm in diameter size) retained their structure on the 
surface of lactose when deposited using ethanol as the vehicle. This demonstrated an interesting 
approach to prepare coated pharmaceutical excipients, where surface coatings are valuable for 
adhesion, active protection or immediate release. In contrast, BSA-loaded poly (lactide) (PLA) 
particles have also been prepared using the single needle electrospraying technique (~particle 
sizes ranged between 0.84 ± 0.18 to 3.95 ± 0.51 µm with yield in the range of 64.3 ± 1.8 to 
80.1 ± 2.6 %) where the encapsulation efficiency of model active was controlled by varying 
the organic/aqueous phase ratio. 
 
1.18 Coaxial EHDA (coaxial electrospraying) 
 
Single-needle and coaxial electrospraying techniques have similar underlying concepts 
regardless of differences to experimental nozzle set-up and alignment. As aforementioned, in 
the single needle electrospraying process, a polymer solution is injected through a capillary 
nozzle after which it is subjected to an external electrical field (by means of high voltage 
supply-usually up to ~30 kV). For coaxial electrospraying, a processing nozzle with two 
enveloped needles (inner and outer needles with different sizes) is aligned concentrically for 
coaxial electrospraying. Using this technique proteins (such as BSA and lysozyme) have been 
encapsulated into PLGA particles with clearly visible encapsulation providing opportunities 
for delicate molecules (e.g. secondary structure of the protein was retained demonstrated using 
CD spectroscopy). The added benefits included sustained release over a 30 days period and the 
activity of lysozyme was more than comparable to values reported in other studies.  
Adaptability in the polymer and drug type, improved drug stability (e.g. for core shell 
encapsulation technologies), high encapsulation efficiency, controlled release and controlled 
particle size generation (micro to nano) are the main advantages of the coaxial electrospraying 
process. Although coaxial electrospraying has been utilised to prepare encapsulated and hollow 
encapsulated nanoparticles, developmental single needle EHDA processes can also be used to 
generate porous structures - albeit not as robust as the coaxial system. For the coaxial format 
the use of multi-material concentric flow becomes a valuable option. Polymers N-octyl-O-
sulphate chitosan (NOSC) and tristearin were explored for the encapsulation of model peptide 
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angiotensin II. High encapsulation efficiencies (~92±1.8 %) and small diameters 100 nm-
300nm were achieved. During the coaxial encapsulation process, parameters were optimised 
to determine peptide stability which was confirmed indirectly in the trout model. Furthermore, 
and interestingly a distinct difference between in vitro and in vivo release outcomes was 
observed which was attributed to environmental and physiological factors. Numerous other 
studies have focused on co-axial technologies for the preparation of layered and coated particle 
technologies using chitosan, PLGA and collagen for matrix and compartmentalised drug 
loading on the micron scale.  
 
1.19 EHDA Spinning (Electrospinning) 
 
EHDA spinning is an efficient and well-known technique for polymer fabrication into well-
defined fibrous materials. This technique involves electrostatic forces to be engaged for 
controlled production of fibres which is similar to the process of electrospraying (for particles). 
Variations arise due to solution (formulation) and intrinsic polymeric (inter and intra 
molecular) properties. Unlike the spraying process, the liquid jet remains intact under the 
instabilities encountered and results in fibre morphology (electrospinning). EHDA spinning 
has rapidly changed fibre making process from a costly, large scale process, to a laboratory 
bench scale with a low cost. The primary characteristic of nanofibers is the high ratio surface 
area to mass (Reneker and Yarin, 2008; Yarin, Koombhongse and Reneker, 2001; Reneker et 
al., 2000). Advantages offered by the electrospraying process (ambient temperature operation, 
size control and facile parameter control) are directly applicable for the electrospinning 
process, however higher output rates are obtained during the electrospinning process technique 
(Gentsch et al., 2010). These methods have been valuable for several drug delivery and 
emerging therapeutic systems. For example the generation of biomimetic extracellular matrix 
(ECM) micro- /nano scale fibres (80 nm – 1.5 µm via EHDA spinning technique) were found 
suitable for tissue engineering (Sell et al., 2007), and have also been used for the fabrication of 
continuous heteroglycan ﬁbres (on the nano scale); which are useful for regenerative medicine 
or drug delivery (Lee et al., 2009). Bovine serum albumin (BSA) nanofibers (from a globular 
protein) have been prepared via electrospinning without chemical cross linking, which have 
potential in biomaterial applications such as wound dressings, suturing and wound closure 
materials due to its biocompatibility, biodegradability and desirable mechanical properties 
being met (DrorY, ZivT, MakarovV, WolfH, AdmonA, ZussmanE, 2008). As was the case 
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with co-axial electrospraying the same format can be deployed to generate layered fibres into 
several material states (e.g. solids, liquids and gases), which provides added benefits of 
compartmentalised structures (Ahmad Z, Nangrejo M, Edirisinghe M, Stride E, Colombo P, 
Zhang HB, 2009). Furthermore, functionalised coating of readily available dressings with a 
superﬁcial layer of synthetic drug loaded fibres was demonstrated using single-needle 
electrospinning. In this instance, PVP - indomethacin composite ﬁbres (~3-5µm in width, 
encapsulation efficiencies of 75% w/w) were directly deposited onto commercial dressing 
systems (Rasekh et al., 2014). This is an extremely valuable approach as electrospun fibres 
suffer from poor mechanical properties if prepared as thin superficial layers or films. Nguyen 
used PLA as fibrous polymeric carrier systems for the delivery of curcumin using 
electrospinning technique for wound healing applications. An increase of curcumin content in 
the PLA-curcumin composite from 0.125 to 6.25 wt% yielded a decrease in nanofibre diameter 
(from 971 ± 274 nm to 562 ± 177 nm). Here, in vivo wound healing was assessed in a mouse 
model showing an increase in wound closure by day 7 for PLA-curcumin (87%) when 
compared with blank PLA nanofibres (58%) (Nguyen, 2013). Moreover, EHDA spinning of 
cellulose acetate with lysozyme and rectorite has successfully generated nanofibers with 
potential in several other areas of combinatorial therapeutic delivery (diameters~500 nm).  
 
 
Figure 1. 10 Schematic electrospinning set up 
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1.20 EHDA Printing 
 
EHDA printing technique is one of the more recent and versatile daughter processes which can 
be applied to a broad range of materials including polymeric systems. One of the main goals 
of any printing technique is to enable ordered structure generation based on a pre-determined 
pathway. The EHDA printing method is valuable as it deploys coarse processing 
needles/nozzles which are significantly different to many printing techniques where the nozzle 
exit diameter usually correlates with the pattern size/droplet. The EHDA printing process is 
electrically driven and operates on identical fundamentals of EHDA technologies (e.g. jet 
formation), however the printing method has distinct advantages over the electrospinning 
process, which include controlled patterning and controlled layering of formulation which is 
valuable for forming with precision. In addition, greater understanding of cell and tissue 
interaction can be achieved which considers structure and chemistry of polymeric materials.  
For example, topographic studies (e.g. using living cells) for material coating-cell interactions 
can be more easily quantified and developed when compared to random electrospun fibres 
providing mechanisms for spatial and temporal resolution assessment (Wang DZ, Jayasinghe 
SN, Edirisinghe MJ, 2005). EHDA printing is a computer-controlled method of depositing 
droplets or threads subject to EHDA in cone-jet mode. The capillary needle is coupled to a high 
voltage power supply (up to 30 kV). The capillary needles used in EHDA printing can be 
several hundred micrometres in size, which is about ten times larger than needles used in 
conventional methods (e.g. ink-jet printing) preventing blockage and allowing easier  
processing (e.g. forviscous suspensions or rapidly evaporating liquids) as well as generating 
much finer droplet sizes (Gupta et al., 2007). EHDA printing of polymethylsilsesquioxane 
(PMSQ, a biocompatible synthetic polymer) solution resulted in complex patterns with printed 
track widths of ~ 100 µm using a nozzle with an orifice diameter of ~750 µm (inner diameter). 
Pure polyurethane (PU) was also printed using an overlapped grid pattern (more complex 3D 
patterning) with a reduced track size of 50 µm (Ahmad, Rasekh and Edirisinghe, 2010). In 
addition to overprinting, the strength of scaffolds depends on the strut size (print width) which 
can be varied readily. PCL was used along with bioactive material nano-hydroxyapatite (nHA, 
~100nm) to deposit structures of bioactive composite materials which resulted in print widths 
of 50 µm using an applied voltage range of 8-11 kV, flow rate of 6 µl/min and working distance 
of 1-2 mm. By adjusting the process parameters; reducing the flow rate to 3 µl/min, printed 
PCL-nHA structures with 5 µm widths were achieved. The benefits of coarse nozzle diameter 
utilisation signified the irrelevance of composite clustering (polymer and ceramic nano-
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crystals) as pure polymeric PCL structures were patterned to the same resolution. Fibroblast 
cell behaviour and in vitro apatite formation using simulated body fluid demonstrated 
biocompatibility and cellular/bio-interaction of both types of patterned surfaces (Rasekh et al., 
2011; Rasekh et al., 2013). More recently, an electrically driven direct-writing technique was 
developed which incorporates coaxial principles to deposit layered (encapsulated) micron 
scaled structures in an ordered or pre-determined pattern using solidified polymers and liquid 
state excipients such as PEG, olive oil and PMSQ polymer (Ahmad Z, Nangrejo M, Rasekh M, 
Stride E, Edirisinghe M, 2013).  
 
1.21 Coaxial EHDA Bubbling 
 
Until recently the main objectives of drug delivery were to improve the solubility of drug, 
increase functionalities of cell targeting and enhance the active bioavailability all in a safe and 
ethical approach. The competence of conventional preparation methods (e.g. emulsion/solvent 
evaporation, spray drying) to produce micro- or nanoparticles has evolved significantly in 
recent times through process enhancement. However, in addition to nanotechnologies, 
microbubbles have also developed into an area of extreme interest due to several attractive 
intrinsic properties. These include imaging potential, trigger-based release (e.g. through 
ultrasound) and several other functionalities arising from the vibrational nature of the thin 
bubble film coating.  Due to the high compressibility nature of the film coat, bubbles serve as 
effective forms of contrast agents for diagnostic purposes in medical imaging applications. For 
example, formulated coatings for microbubbles may also propel their utility as active carrier 
systems, tracing through the body and terminated precisely to release active (using low and 
high intensity triggers, respectively). This localised approach can be used to reduce side effects 
of chemotherapies, but size distribution, drug content and destruction are critical; and these are 
not readily provided by numerous existing bubble preparation techniques. For example, 
generating microbubbles using sonication or agitation results in wide-ranging size 
distributions, which means it becomes essential to filter microbubbles to yield samples <10 
µm, as greater sizes can cause embolism in vivo. 
Coaxial EHDA bubbling also utilises similar fundamental principles to those mentioned 
previously for structure engineering. The difference, however, is the requirement of gas to be 
infused into the inner needle, which is surrounded by a liquid medium in the outer needle. 
Typically, in the bubbling process much higher infusion rates (of air) are deployed and new 
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jetting modes have also been identified due to the interacting nature of multi-phase flow (e.g. 
coning mode). Using this process (EHDA bubbling) novel hollow spherical structures of silk 
fibroin have been fabricated which arise from microbubble forming. Upon preparation 
microbubbles displayed diameters in the range of 240-1000 µm, which can be controlled by 
adjusting processing parameters as well as the use of combinatorial materials as polymer 
composites. Furthermore, BSA bubbles have also been developed using the same process and 
cross-linking to show applications in biosensors (thin porous film membrane engineering), 
drug delivery (coated BSA bubbles) and tissue engineering (3D porous scaffolds) (Ekemen et 
al., 2011). Additionally, BSA coated bubbles (via bubbling) also record a response to 
ultrasound demonstrating their potential in both trigger-based release and as potential imaging 
agents (Ekemen et al., 01). Finally, the preparation of multi-coated bubbles (duplex) using the 
EHDA process is also possible which paves the way to several opportunities for 
compartmentalised drug loaded and trigger-based release via ultrasound application. 
 
1.22 EHDA Cell Electrospinning 
 
Synthetic biodegradable matrices possessing similar size and mechanical properties of the 
extracellular matrix (ECM) can be generated using the electrospinning process. As in vitro 
studies and cell infiltration in to pre-prepared electrospun fibres or structures is time consuming 
and prone to cellular integration challenges, the development of a one-step matrix-cell process 
is extremely valuable. The electrospraying of smooth muscle cells (SMCs) was demonstrated 
in tandem with electrospinning of poly (ester urethane) urea (PEUU) yielding a hybrid tissue 
engineered blood vessel construct in one-step. Hematoxylin and eosin (H&E) staining 
confirmed qualitatively uniform SMCs. The samples were also tested for their biomechanical 
properties, which demonstrated appreciable strengths. Furthermore, other studies in this area 
have utilised both polymeric matrix materials and living cells into one single nozzle 
formulation which has demonstrated cell viability. These present exciting potentials to develop 
and replace failing bodily organs which becomes ideal when conventional and novel 
engineered dosage forms do not respond. On point, the interchangeable nature of EHDA 
technology demonstrates its value again, this time for therapies we are currently beginning to 
understand and are yet in their infancy. While these are exhilarating developments, efforts have 
also been directed towards scaling up simple EHDA processes which will be transferable to 
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various sub-classes of EHDA processing.  These are timely developments which are essential 
to meet demand once such technologies have matured fully. 
 
Concluding remarks 
 
Synthetic and naturally occurring polymers have been utilised in both well established and 
emerging pharmaceutical (and therapeutic) materials and dosage forms. The utilisation of these 
materials has also been expanded from serving as mere fillers and single function matrix 
materials to controlled release excipients and multi-functional enabling structures. The latter 
has been expedited due to further functionalisation or careful engineering. EHDA technologies 
are robust technological platforms permitted the one-step engineering of a selection of 
polymers (and therefore integration of their unique properties) on several scales which are able 
to meet requirements from the past and those currently emerging as future therapies including 
fibres, nanoparticles and bubbles.  
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Table 1. 2 EHDA of synthetic polymers for use as drug delivery systems   
Polymer 
Type 
 Polymer (s) Chemical Structure (s) 
EHDA 
Technique 
Name of 
Drug/ Active 
Application 
Structure & 
Dimension 
Additional Comments Ref 
 
PCL-PPE-
EA 
 
PCL 
PCL 
PPE-EA                       
ESy 
Bovine serum 
albumin 
(BSA) 
Therapeutic  
agent 
delivery and 
advanced 
controlled 
release 
Size range 2-
8 µm. Core 
shell 
particles 
Core shell particles 
prepared using a single 
needle ESy technique. 
Achieved using an 
emulsion as the liquid 
formulation. Reduction 
in burst release. 
53 
 PLA 
 
 
 
ESy 
Bovine serum 
albumin 
(BSA) 
Therapeutic  
agent 
delivery  
0.84 - 3.95 
µm. Solid 
matrix type  
Encapsulation 
efficiency Of BSA was 
improved by an increase 
in organic phase ratio. 
However, these ratios 
also impact the physical 
properties o materials 
58 
 PLGA 
 
ESy Paclitaxel 
Therapeutic  
agent 
delivery 
Down to 250 
nm 
Particle surface and 
overall morphology is 
dependent on polymer 
concentration. 
54 
Synthetic PMSQ 
 
Cox, ESy, 
ESp, EDHP 
Bioactive 
nanoparticles 
 Advanced 
controlled 
release 
including use 
of trigger. 
Patterning 
and 
advanced 
coatings. 
Various 
structures 
and sizes  
prepared 
(nanometre 
and 
micrometre) 
Multiple phase 
encapsulation into 
micron scaled 
structures. Controlled 
release of loaded 
materials demonstrated 
using an ultrasound 
trigger. Layering of 
structures possible with 
74 
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hollow, solid and liquid 
phase. 
 PVP 
 
 
 
 
ESp Indomethacin 
Medicated 
wound 
dressing and 
patches 
 
2.58-5.22 
µm. Smooth 
fibres. 
Drug loaded fibres 
dissolve quickly to 
release active. Direct 
deposition on to 
existing dressings 
provides mechanical 
robustness to an 
invisible spun thin 
coating.  
75 
 PLA 
 
ESp Curcumin 
Medicated 
Wound-
healing 
patches 
971-562 nm 
Smooth 
Increasing the 
Curcumin content leads 
to a reduction in spun 
fibre diameter. Drug 
loaded PLA fibres 
demonstrated quicker 
healing when compared 
to control blank fibres 
in mouse models. 
76 
 PEG-PLGA 
 
Cox ESy 
BSA and 
lysozyme 
Therapeutic 
agent  
delivery and 
advanced  
controlled 
release  
800nm–10.4 
µm. Various 
surfaces 
(smooth to 
porous). 
Drug release sustained 
for up to 30 days. 
Bioactivity of lysozyme 
maintained during the 
production process 
(90%) suggesting great 
potential for other 
sensitive bio-actives 
59 
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 PLLA-PLGA 
 
PLLA 
 
 
PLGA 
Cox  ESy 
Paclitaxel and 
Suramin 
Therapeutic 
agent  
delivery and 
advanced  
controlled 
release 
15–20 µm 
The use of two different 
types of drugs 
(hydrophilic and 
hydrophobic) into a 
single particle system 
via 
compartmentalisation is 
demonstrated. The rate 
of drug release can be 
controlled by altering 
the quantity of inflow 
for each formulation 
during Cox ESy 
66 
      PEUU 
 
CellESy 
and ESp 
Living Cells 
(smooth 
muscle) 
Tissue 
Engineering 
and 
regenerative 
medicine 
Sub micron 
Overcoming issues 
relating to integration 
and viability of cells 
into separately 
engineered matrix 
systems. The process is 
one-step  
93 
 PCL 
 
EHDP 
Bioactive 
nanoparticles 
Enhanced 
patterned 
coatings for 
improved 
cellular 
interaction 
Spots, relics 
and tracks. 
Tracks  
optimised to 
~5µm 
Active hydroxyapatite 
nano particles 
embedded into printed 
PCL matrix tracks 
demonstrate in vitro 
bioactivity (apatite layer 
formation in SBF). 
Structures morphology 
also variable based on 
formulation solution 
concentration (PCL).  
81 
 42 
 
Table 1. 3 EHDA of natural polymers for use as drug delivery systems   
Polymer 
Type 
Polymer (s) Chemical Structure (s) 
EHDA 
Technique 
Name of 
Drug/ Active 
Application 
Structure 
and 
Dimension 
Additional Comments Ref 
 
Gliadin, 
gliadin/gela
tin 
 
 
Gelatine 
ESy 
Cyclophospha
mide 
Cancer therapy 
and controlled 
drug delivery 
Mean size 
between 218-
450 nm 
Gliadin based particle systems 
released drug over a 24-hour 
period. However, the rate of 
release can became expedited   by 
incorporating gelatin into the 
system. Cultured breast cancer 
cells became apoptotic (24h) 
55 
 
N-octyl-O-
sulphate 
chitosan 
and 
tristearin 
N-Octyl-
O-sulphate chitosan
 
Tristearin 
Cox ESy, 
ESy 
Angiotensin II 
Delivery of 
water-soluble 
peptides and 
proteins. 
Controlled 
release.  
100-300 nm 
Peptide stability during the ESy 
process was demonstrated. A 
viable processing range (e.g. for 
applied voltage) was obtained 
enabling peptide to remain intact. 
Release of peptide was gradual, 
and the burst phase was reduced. 
Interestingly, in vivo model 
(trout) demonstrated a quick on-
set of action. 
64 
 
 
 
Silk, BSA 
and PEO 
 
 
 
Cox BBg - 
Tissue 
engineering 
applications 
and 
regenerative 
medicine 
240-1000 µm 
Greater control on pore size and 
distribution using this process- 
ideal for biomaterial applications. 
Furthermore, as the BBg process 
requires high inflow rates of gas, 
this has shown to impact on β-
sheet packing within the 
microstructure. This in turn 
impacts on mechanical properties 
of resulting scaffold type 
materials (e.g Tensile) 
89 
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Natural 
Chitosan 
 
 
 
 
ESy Ampicillin 
Drug delivery 
and controlled 
release. 
Potential in 
nasal and GI 
tract delivery 
Mean size 
~520 nm. 
Solid 
spherical 
particles 
Particles demonstrated 
encapsulation efficiencies of 
~80.4%. Particles also 
demonstrated clear inhibition 
zones when cultured on E. Coli. 
Interesting feature to note was the 
applied voltage rate of 28 kV. 
65 
 Collagen 
 
R=neutral side chain 
Cox ESy 
and ESy 
Theophylline 
Pulmonary 
drug delivery 
and controlled 
release 
693nm -3 
µm 
Distinct differences in size and 
surface morphology was observed 
when particles were prepared 
using ESy and Cox ESy. The 
process required an addition of 
salt to permit particle preparation 
for acetic acid based vehicles.  
67 
 
Cellulose 
acetate 
 
ESp and 
ESy 
Lysozyme & 
Rectorite 
Controlled 
release and 
medicated 
wound 
dressings and 
patch systems 
Mean 
diameter 
range ~ 375-
580 nm. 
Smooth 
fibres 
This approach deployed a two 
step strategy using both ESy and 
ESp. Cellulose fibres (-ve charge) 
spun first and then coated with 
sprayed active (+ve charge) to 
yield a fibrous composite coated 
material. The concentrations 
Lysozymne impacts fibre 
structure. Samples demonstrated 
excellent antimicrobial properties 
against both gram +ve and –ve 
models (E. coli and S. Aureus). 
Release rates were determined 
over a 2 hour period after which 
the activity of Lysozyme is lost 
(in distilled water).  
 
 
 
 
 
77 
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 Alginate 
 
 
 
ESy Silk Sericin 
Protein 
delivery with 
potential 
applications as 
antioxidant 
and physical 
property 
enhancer 
Particle 
range 264-
284 µm. 
Some 
variation in 
particle 
shape. 
 
Relatively high encapsulation 
efficiencies were achieved when 
the ESy approach deployed 
(>80%).  Evidence of release 
kinetic control. 
56 
 BSA 
 
 
 
ESy - 
Advanced 
particle 
coatings (e.g. 
pulmonary 
delivery) 
~700 nm, 
spherical 
A novel approach to coat   one 
excipient (lactose) with another 
(BSA) but in this instance the 
coating material retains the 
sprayed particle geometry (for 
ethanol based formulations). Due 
to ambient process conditions; 
protein particles were stable. 
57 
 
 
BSA 
 
 
 
 
 
Cox BBg - 
Drug delivery, 
bio-sensing 
and 
regenerative 
medicine  
Multiple 
BSA formats 
(porous 
films, 
scaffolds and 
standalone 
bubbles) 
Structure generation controlled by 
varying BSA solution parameters 
(concentration) and cross linking 
of BBg generated structures. 
Engineered systems demonstrate 
biocompatibility when tested on 
mouse cell lines. Improved 
biosensor properties achieved 
when compared to traditional 
membrane (prepared using 
established method) 
90 
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1.23 Quality by design (QbD) framework 
 
Quality by design (QbD) in pharmaceutical development is a concept which is defined as 
systematic approach to development that starts with predefined objectives and emphasises 
product and process understanding and process control, based on quality risk management 
(Buttini et al., 2018; Politis and Rekkas, 2011; Ko et al., 2018). The international conference 
on harmonisation (ICH) on QbD insist on process understanding and knowledge management. 
ICH Q8, ICH Q9, ICH Q10 and ICH Q11 are the guideline on QbD. These mudlines direct to 
structuring of the risk based approaches across the product life cycle and addresses quality of 
the systems used to formulate the pharmaceutical products, (Bastogne, 2017; Rathore and 
Winkle, 2009) and moreover provides a framework to support the assurance of product quality 
as well as continues improvement over the product life cycle (Dispas et al., 2018; Csóka, 
Pallagi and Paál, 2018; Thakur, Kaur and Sharma, 2017; Ko et al., 2018; Bastogne, 2017). 
QbD following three principles which includes first, to assure product efficacy need to identify 
target product profile (TPP) and critical quality attributes (CQA), second, a risk analysis on 
drug substances, potential excipients and the definition of design space, third, design a 
manufacturing process to ensure the reproducibility of the process (H. Wu and Khan, 2009; 
Stults et al., 2015; Rahman, Siddiqui and Khan, 2013).  
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Chapter 2 Methods and materials 
 
This chapter summarises the materials and methods used in this development. Materials will 
be presented according to the information provided by the manufacturers. Methods are 
presented as a general protocol in this chapter and will be discussed more in corresponding 
chapter.  
2.1 Materials 
 
Following materials were used to carry out the experiments. 
 
2.1.1 Polymers used in this study 
 
Polyvinylpyrrolidone (PVP), Mw 1300000, used as binder in pharmaceutical tablets. 
Methocel is a water-soluble polymer which derived from cellulose. Methocel products are used 
as thickeners, binder and water retention agents  
Ethocel is water insoluble, organic soluble polymers which used in many pharmaceutical 
products as binders, film formers and time release agents.  
hydroxypropyl methylcellulose (HPMC) Mw 1261.45 is a semisynthetic viscoelastic 
polymer which is used in oral pharmaceutical medication as control release and ophthalmic 
lubricant which is available in many commercial products 
Tween 80 is a viscos and synthetic compound which is used as emulsifier and surfactant in 
food and cosmetic products. 
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Table 2. 1 Polymer with their chemical formula and functions  
Compound Chemical formula Mulocular structure Function 
 
 
PVP 
 
 
(C6H9NO)n 
 
 
 
Binder, coating or film forming, release agent to 
control drug duration of action time. 
 
 
Methocel 
 
 
CH2CH(OH)CH3 
 
 
 
Binder, control release 
 
 
Ethocel 
 
 
C6H7O2(OR1)(OR2) 
 
 
 
Binder, coating or film forming, control release 
 
 
Hydroxypropyl 
methylcellulose 
(HPMC) 
 
 
C56H108O30 
 
 
 
Control drug release 
 
 
Tween 80 
 
 
C32H60O10 
 
 
 
Solubilizing agent (surfactant) 
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2.1.2 Anti-inflammatory drugs (NSAID) used 
 
These NSAID drugs are potent analgesic. Due to their use for many treatments, they have been 
prepared in verity of formulations including tablets, capsules, injections, drops, gels, 
suppositories and ointment. The extensive worldwide use of these drugs has driven researchers 
to develop and evaluate new methods using numerous analytical techniques.  
NSAID (Indomethacin, Piroxicam, Ketoprofen, and Diclofenac sodium), and 
PVP (1.3 × 106 g/mol), were purchased from Sigma-Aldrich (Gillingham, UK). Ethanol 
(HPLC grade) was obtained from Fisher Scientific (Loughborough, UK). Acetonitrile (HPLC 
grade) was obtained from Sigma-Aldrich, Germany. Ethocel E-10, HPMC and surfactant 
Tween® 80 were purchased from DOW Chemical Company-UK. Buffer pH 6.8 solution 
simulating saliva was prepared using NaCl (0.850 g), Na2HPO4 (0.200 g) and NaH2PO4 2H2O 
(0.129 g) in 100 mL of distilled water. All chemicals and solvents were of analytical grade and 
all components of buffer solutions were purchased from Merck (Germany). 
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Table 2. 2 NSAID drug and their chemical formula and functions  
 
Compound 
 
Chemical formula  
 
Molecular structure 
 
Function 
 
 
Indomethacin 
 
 
C19H16ClNO4 
 
 
Nonsteroidal anti-
inflammatory drug 
 
 
Piroxicam 
 
 
C15H13N3O4S 
 
 
Nonsteroidal anti-
inflammatory drug 
 
Ketoprofen 
 
 
C16H14O3 
 
 
Nonsteroidal anti-
inflammatory drug 
 
 
Diclofenac sodium  
 
 
C14H10Cl2NNaO2 
 
 
Nonsteroidal anti-
inflammatory drug 
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2.2 Methods 
 
2.2.1 Electrospinning formulations 
 
Electrospinning is a one step process in which the formulation solution atomised by a nozzle. 
Formulation compositions are listed in a Tables for each chapter. Polymer solutions (100 mL) 
were prepared using a base of ethanol and distilled water (80/20 v/v%). PVP (5% w/v) was 
then dissolved in the vehicle through magnetic stirring (Jenway, Staffordshire, UK). Selected 
co-polymers (2 and 5% w/w of PVP) and NSAID (5% w/w of PVP) were added to each 
formulation under stirring (at ambient conditions) until complete dissolution. Paraffin film was 
used to seal resulting solutions to prevent solvent evaporation. Finally, four additional 
formulations were prepared using selected solutions of PVP, co-polymers (at 5% w/w) and 
NSAID but with addition of 5%w/w Tween® 80 (of PVP). All solutions were prepared at the 
ambient temperature. The conventional pharmaceutical function of excipients used in this study 
is shown in Table 2. 1. 
 
2.2.2 Solution characterization 
 
2.2.2.1 Electrical conductivity 
 
Most of solution conduct electricity to some extent. The ability of solution to conduct electricity 
can be measured by using conductive meter. Different materials have different effect on 
conductivity of formulation. For example, adding salt will increase conductivity of 
formulation. The current flows by ion transport. The more ions presented in the solution the 
more conductive the solution will be otherwise the solution will be resistive to current flow. 
Conductivity is measured by immersing the sensor into the solution. Using Ohm law; the 
current pass through between electrodes is proportional to the current across the two electrodes. 
 
𝐼 =
𝑉
𝑅
 
Equation 2. 1 
Where I (units of amperes) is current through the conductor, V (units of volts) is the voltage 
measured and R (units of ohm) is the resistance of the conductor. 
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Figure 2. 1 Digital image of a Mettler Toledo Electrical conductivity meter 
 
2.2.2.2 Viscosity 
 
One of the properties of liquid is its resistance to flow, this can therefore be measured by a 
viscometer. Since changes in viscosity reflect changes to molecular weight, viscometer is used 
to characterise the formulations. Viscosity of the formulation (drug and polymer) was 
determined by using a sine wave vibra viscometer (mPa.s). Change in viscosity on real time 
basis can be detected by thin and small size sensor plate. The electric current which is needed 
to vibrate the two sensor plates at constant frequency of 30Hz is measured as viscosity. This is 
useful technique in determining the ideal polymer or combination of polymers for electrospray 
or electrospinning as flow rate and viscosity are main aspect to be considered for this 
development.  
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Figure 2. 2 Digital image of Sine-wave vibra viscometer (SV-10) 
 
2.2.2.3 Surface tension 
 
Du Noüy ring method was employed to measure surface tension of formulations. The force 
which acting on a ring (wetted length) because of the tension of moving ring from one phase 
(solution) to another is measured. This is done by inserting the ring into solution at the surface 
of solution. When the ring is forced out of the surface, the required force is the surface tension 
of that solution and can be measured using the following equation:  
 
 
Equation 2. 2 
 
              
Where σ is surface tension, F is the force, and L is the wetting length of the ring 
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Figure 2. 3 Digital image of Torsion balance (A) and Schematic diagram of the Du Noüy ring 
method (B) 
 
2.2.2 Electrospinning 
 
The basic arrangement for electrostatic atomisation is, a nozzle connected to the high voltage 
power supply and supplied with a liquid (formulation) to be atomised. As the solution is 
stretched with electrostatic repulsion between the surface and the evaporation solvent the 
droplet changes its shape to conical and, if the voltage is high enough, a liquid filament is 
ejected from a cone peak. 
During electrospinning the liquid is flowing out of the nozzle and is forced by an electrical 
field to be dispersed into fine fibres. Controlling of parameters such as the flow rate of the 
liquid and the voltage give the chance of formation of controlled fibre size. 
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Electrospinning technique involves the use of a high voltage to induce the formation of a fibre 
(micro or nano scale) from a liquid. As the viscous polymer solution is stretched with 
electrostatic repulsion between the surface and the evaporation solvent a solid fibre will be 
generated. In electrospinning process parameters such as electric field, diameter of needle, flow 
rate of solution, etc. and the property of solution such as viscosity, concentration surface 
tension, etc. have a direct effect on the morphology and diameters of fibres Electrospinning 
can prepare particularly fine fibers from a polymer solution by utilizing a simple one step, 
electrostatic interactions and elongation of the viscoelastic jet system process. 
 
 
Figure 2. 4 Electrospinning equipment’s (Pump, syringe, needle, collector, and voltage 
supply)  
 
2.2.3 Differential Scanning Calorimetry (DSC) 
 
Differential scanning calorimetry (DSC) is one of the thermal analytical techniques which 
allows for direct study of thermal stability of drugs (Spink, 2008). The principle of DSC is that 
it monitors heat flow between a sample and an inert reference sample during a specified 
temperature (Garbett et al., 2009). In DSC, a sample and a reference are heated or cooled at the 
same rate (Farah et al., 2018). The heat flow difference required to maintain zero temperature 
between the sample and the reference is measured as function of time and temperature (Knopp 
et al., 2016; Johnson, 2013). The purpose is to deliver an assessment of the activation energy 
at the glass transition temperature, as well as of the fragility index, of amorphous NSAID from 
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DSC data. Upon heating, the fibres undergo some thermal induced event such as; endothermic 
or exothermic reaction. These reaction causes changes in the differential heat flow which is 
then recorded as a peak on the DSC thermogram (Clas, Dalton and Hancock, 1999). The area 
under peak is directly proportional to the enthalpic change and its direction indicates whether 
the thermal event is endothermic or exothermic (Senatra, 2006). The endothermic reaction, in 
which heat flows into the sample, the system absorb energy from surrounding usually in the 
form of heat. However, exothermic reactions in which energy flows out of the samples in the 
form of heat. DSC helps to study the transitions such as apparent denaturation melting 
temperature (Tm), crystallization, and glass transition temperature of NSAID formulations.  
DSC methods has the advantage of being a relatively fast technique with most analysis taking 
less than thirty minutes for each sample. Different type of materials can be analyzed by DSC 
e.g. solid, liquid, films and powder. 
DSC was performed using a PerkinElmer Jade DSC differential scanning calorimeter 
(PerkinElmer Ltd., Shelton, CT, USA). The heating flow rate was calibrated with pure indium 
standard. Samples (3.5–4.2 mg) were placed into an aluminum pan (Perkin Elmer) and sealed. 
Samples were heated from 20 to 200 °C at a heating rate of 10 °C/min under a nitrogen purge 
of 70 mL/min. 
 
Figure 2. 5 Digital image of Differential Scanning Calorimetry (DSC) 
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2.2.4 Thermal Gravimetric Analysis 
 
Thermal gravimetric analysis (TGA) is another thermos analysis technique like DSC.  TGA 
provides very useful and relevant information for materials of interest. TGA measures and 
record melting point, transition temperature and weight loss of materials (Bach and Chen, 
2017). TGA measures the changes in a sample as a function of temperature or time. Changes 
will appear in chemical or physical properties of samples and therefore weight loss. Thermal 
stability of sample can be achieved by two methodologies; fixing the temperature over a range 
of time or by ramping the temperature over a fixed time.   
Thermal behavior of fibrous films was analyzed using a thermal gravimetric analyzer TGA 
(Perkin Elmer Pyris 1 TGA). Each sample was placed in an aluminum pan (TGA, Perkin 
Elmer), weighted (7–10 mg) and heated using a temperature range of 20 to 800 °C in nitrogen 
atmosphere, using heating rate of 10 °C/min. 
 
 
Figure 2. 6 Digital image of Thermal gravimetric analysis (TGA)   
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2.2.5 Fourier Transform Infrared Spectroscopy (FTIR) 
 
Infrared spectroscopy is divided into three segments, the near-IR, mid-IR and far-IR. Fourier 
transform infrared spectroscopy (FTIR) is an analytical technique used to study the interactions 
between infrared light with matter. FTIR is a common analytical technique that is popular and 
used vastly in pharmaceutical sample identification. FTIR is a non-distractive, fast and 
quotative technique which measures the absorption of infrared radiation by the sample material 
versus wavelength in line or off line (Großhans et al., 2018; Alvarez-Ordóñez et al., 2011). A 
spectrum is produced representing the component of the sample in relation to their functional 
group and bonds in term of peak which also have a corresponding wave number and therefore, 
identify molecular compound and structures (Kamnev et al., 2018). Upon radiation of a 
material by infrared, molecules are excited into higher vibration state. The result wavelengths 
of sample which identify the functional groups present are characteristic of its molecular 
structure (Hou et al., 2018). 
The chemical structure of raw materials and formulated fibrous films was analyzed by Fourier 
transform infrared spectroscopy (FTIR Platinum-ATR fitted with Bruker Alpha Opus 27 FT-
IR). Infrared spectra were recorded in the range 4000–400 cm− 1 using 30 scans at a resolution 
of 4 cm− 1 for each sample. 
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Figure 2. 7 Digital image of Fourier Transform Infrared Spectroscopy (FTIR) 
 
2.2.6 Raman spectroscopy 
 
Identifying the properties of raw materials and excipients are important in development of 
pharmaceutical products. On the other hand, helps to regulate the critical process parameters 
and quality attributes (Paudel, Raijada and Rantanen, 2015). Raman spectroscopy was 
employed as feasible application to PAT to investigate intermolecular vibration, rotational and 
other low frequency of formulations in the solid state. In Raman spectroscopy laser interact 
with the system and resulting in shift into the energy of laser photons (Doty and Lednev, 2018). 
The shift gives information about molecular bonds and the molecule itself (Kong et al., 2015). 
Therefore, provides the product chemical and structural information. Raman spectroscopy is a 
nondestructive, fast, and easy technique and facilitate quantitative and qualitative analysis 
(Maurer et al., 2018; Bumbrah and Sharma, 2016).   
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Raman spectra were collected using a FORAM® Raman spectrometer (Foster & Freeman Ltd) 
equipped with a 785 nm laser, using 30 scans at a resolution of 4 cm− 1. Raman spectra were 
collected between 3300 and 100 cm− 1. 
 
 
 
 
Figure 2. 8 Digital image of FORAM® Raman spectrometer (Foster & Freeman Ltd) 
 
2.2.7 Scanning Electron Microscope (SEM) 
 
Scanning electron microscopy (SEM) is a widely used image analysis in many scientific 
applications. SEM operates at high vacuum. Emission gun generate beam of electron and then 
the beam of electron pass through electromagnetic lenses and therefore, produce thin beam of 
electrons (Lewis, 1992). Thereafter, the beams scan the surface of a sample with a focused 
beam of electron and thereafter, electrons emitted from the surface to be collected by detector 
(Klang et al., 2012; Bogner et al., 2007; Panessa-Warren, 1983). Interaction of electrons with 
atoms in the sample yield indications that comprise sample surface topography and 
composition (Klang, Valenta and Matsko, 2013; Carter and Shieh, 2015; Singh, 2016). SEM 
with secondary electron detector can visualise surface morphology, shape, and surface of 
samples. On other hand optimisation of particle size, roughness and morphology of 
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pharmaceutical materials can be achieved. Furthermore, these aspects are the key crucial in 
compounding process and product solubility pharmaceutical products (in this study fibres) 
either comprising active pharmaceutical ingredients (API) or excipients.  
SEM was employed to analyses the morphology of the fibres. It is also can be used as 
identification tool, as each material has a unique and different effect on fibres structure as well 
as their morphology.  
 
 
Figure 2. 9 Scanning electron microscopy of fibres at 5000 and 25000 magnifications.  
 
Scanning electron microscopy (SEM) was conducted using SEM Carl Zeiss EVO® HD15 
(Carl, Zeiss, Oberkochen, Germany) at an accelerating voltage of 5 kV. Fibrous membranes 
were mounted onto a sample holder (aluminum stub) using double sided tape. To prevent any 
overcharging, samples were sputter coated (S150B, Edwards, Crawley, West Sussex, UK) by 
exposing samples to a gold atmosphere at 5 Pa. Each sample was coated for 105 s twice. Fibre 
diameters were assessed via Image Tool program, and fibre diameter distribution was 
determined using a random sample size of n = 100 fibres.  
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Figure 2. 10 Digital image of scanning electron microscopy (Carl Zeiss EVO® HD15) 
 
2.2.8 Atomic force microscopy (AFM) 
 
Characterisation of small specimens become easy with the help of microscopes. Microscopes 
uses photons and electrons (probes) in optical and electron microscopies, respectively. Atomic 
force microscopy (AFM) is a high-resolution scanning probe microscopy which look at 
samples on the atomic level. This technology is common used in nanotechnology. AFM uses 
the impact of the sample force on the probe to form a three-dimensional image of sample 
surface (Wang and Nie, 2018; de Pablo, 2018).  
AFM does not use laser or irradiation, and this is its advantage upon other technologies (e.g. 
electron microscopy and optical microscopy).  Therefore, does not need to create a vacuum to 
guide the beam or staining (metal coating) the sample (Chang et al., 2012; Liu and Yang, 2018).  
Three dimensional analysis was also performed using atomic force microscopy (AFM) [AFM 
5420 (Agilent Technology, Berkshire, UK)]. AFM was conducted in contact mode using a 
radius tip of 15 μm and a cantilever spring constant of 0.2 N/m. 
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2.2.9 X-ray diffraction (XRD)  
 
Atomic structure of materials necessary to understand and predict properties of material under 
study. XRD has shown that has potential use in studying the structure of materials (Petkov, 
2008).  
X-ray diffraction (XRD) is a rapid and nondestructive analytical technique which used to in 
provide information about structural, physical properties and chemical composition of 
materials in pharmaceutical industry (Brittain, 2003). The technique offers identification and 
characterization of materials based on their diffraction outline.  In this technique an X-ray beam 
hit the sample and scattered intensity from atom within the target sample observed as 
wavelength or energy. The cooperation of the incident beams with the sample yields 
constructive interface. Thereafter, the diffracted beams are detected and processed. Thus, XRD 
has proven to be a valuable technique in research and pharmaceutical industry for crystalline 
materials (Petkov, 2008; Rompalski et al., 2016).  
Sample crystallinity was evaluated using XRD analysis performed on a Bruker D8-Advance 
diffractometer, operating at 40 kV and 40 mA whilst using Cu Ka1. A scanning rate of 
0.35 s/step was used. Spectra were collected in 2 theta from − 3 to + 160°. 
 
 
Figure 2. 11 Digital image of X-ray diffraction (XRD 
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2.2.10 Encapsulation efficiency (EE) 
 
Precisely weighted amounts (10 mg) of each fibrous film sample was dissolved in 20 mL of 
PBS in capped glass vials under magnetic stirring for 15 min to ensure complete dissolution. 
The resulting solutions were centrifuged at 4500 rpm for 15 min, and quantification of NSAID 
drugs were performed on the resulting supernatants using UV–Vis analysis at 320, 354, 260 
and 276 nm for Indomethacin, Piroxicam, Ketoprofen, and Diclofenac Sodium respectively 
(UV–Vis spectrophotometer, Shimadzu, UVmini-1240). Experiments were run in triplicate. 
Drug content was calculated according toError! Reference source not found.. 
 
Encapsulation efficiency (%
w
w
) = (
Weight of  loaded drug
Weight of drug in fibre
) × 100 
Equation 2. 3 
 
Drug encapsulation efficiency is an important index for drug delivery systems. Where 
encapsulation efficiency is the percentage of drug that is successfully entrapped into the 
nanofibres.   
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2.2.11 In vitro release studies 
 
Release studies were conducted in capped glass vials in an agitating water bath at 37 °C. 5 mg 
of every sample was sunk to the bottom of vials filled with 20 mL of PBS buffer solution 
pH 6.8 (Ladrón De Guevara-Fernández, Ragel and Vallet-Regí, 2003; Karavasili et al., 2014). 
At predetermined time intervals samples of 1 mL were withdrawn and replaced with equal 
volumes of fresh and pre-heated to 37 °C buffer solutions. Samples were centrifuged at 
2500 rpm for 15 min, and the supernatants were analyzed with UV–Vis at 320, 354, 260 and 
276 nm for Indomethacin, Piroxicam, Ketoprofen, and Diclofenac Sodium respectively. All 
experiments were repeated four times. The calibration curve of al NSAID drugs in PBS pH 6.8 
showed good linearity (r2 = 0.999) in the concentration range 1–40 ppm.  
 
2.2.11.1 Release kinetic modelling 
 
The system that drug get into the body is called drug delivery system. It includes active drug, 
bio active agents and other excipients which is used as vehicle for administration of the active 
drug. In recent years drug therapies with polymer-based drug delivery systems has been 
improved largely. Such a system essentially improves patient compliance and transport drug 
molecules effectively. To achieve appropriate drug release and proper absorption of active drug 
certain tests must be performed (e.g. dissolution). Polymer delivery system can be completed 
with mathematical modelling to control release system. Mathematical modelling can reduce 
the amount of experiment needed by help to predict the drug release rate and diffusion 
behaviour from the formulation. Therefore, the development of mathematical models facilitates 
us with prediction delivery performance. Many mathematical models have been developed to 
demonstrate different drug delivery system. Various models such as zero order, first order, 
Higuchi, and Korsmeyer-Peppas can be used to plot in-vitro release profiles.  
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2.2.11.2 Zero order Kinetic  
 
The rate of drug release is constant with zero order kinetic and the release independent to drug 
concentration of the dissolved substance.  
 Q = Q0 + K0t   Equation 2. 4 
 
Where Q is the amount of drug release at time t, Q0 is initial amount of drug, K0 is the zero 
order rate constant and t is time at which the amount of drug released.  
 
2.2.11.3 First order Kinetic 
 
The rate of drug release is proportional to the drug concentration with first order. The rate of 
release increases with the increase in drug concentration. 
 Log Qt = Log Q0 - Kt/2.303 Equation 2. 5 
 
Where is Qt the amount of drug unreleased at time t, Q0 is initial amount of drug, K is first 
order release constant, and t is time in hours.  
 
2.2.11.4 Higuchi model 
 
The Higuchi model proposes that the drug release by diffusion and relates drug concentration 
to the square root of time.  
 Ǫ = KHt1/2   Equation 2. 6 
 
Where Q is the quantity of drug released at time “t” per unit area, KH is the Higuchi dissolution 
constant and t is time in minutes. The cumulative percentage of drug release against square 
root of time plot gives straight line.  
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2.2.11.5 Korsmeyer Peppas model 
 
The Korsmeyer-Peppas is implies that the fraction release of drug is exponentially related to 
release time. Diffusion or non-fickian diffusion refers to combination of both diffusion and 
erosion rate release.  
 Mt / M = Kmtn       Equation 2. 7 
 
Where Mt is the amount of drug released, M is the total amount of drug in dosage form, Km is 
kenotic constant, n diffusion or release exponent, and t is time in hours. The linear regression 
of log (Mt / M) against log t plot estimate the n value.  
Table 2. 3 Iinterpretation of diffusional release from polymeric films.  
Release exponent (n) Drug transport mechanism Rate as a function of time 
0.5 Fickian diffusion t-0.5 
0.45< n = 0.89 Non- Fickian transport t n-1 
0.89 Case II transport Zero order release 
Higher than 0.89 Super case II transport t n-1 
 
Drug release data was further assessed using the Higuchi model as shown in (Error! Reference 
source not found.). The mathematical model is necessary to study the release mechanism of 
the prepared formulation. The Higuchi model was selected based on previous studies which 
indicate diffusive mechanisms for drug entrapped within filamentous matrixes (Kataria et al., 
2014; Maleki et al., September 2016; Immich et al., 2013). The Higuchi model specifically 
describe the release rate of drug from a matrix system. In this system the drug dissolved from 
surface layer of matrix to the external solution and therefore, the dispersed drug moves into the 
interior as a forward-facing.  
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Chapter 3 Preparation of buccal film with different polymer and 
polymer-copolymers 
 
3.1 Introduction 
 
Active pharmaceutical ingredients (APIs) can be administrated to the body using various 
routes; broadly classified as parental or enteral. Selection of a specific route (e.g. oral, 
transdermal, i.v.) is driven by the intended purpose, method of action and several patient 
focused factors (Cook, 2007). The administration route is a major aspect of drug delivery as it 
is responsible for drug accessibility. Therefore developments yielding novel dosage forms or 
enabling technologies which overcome limitations associated with conventional systems 
become essential (Gurruchaga et al., 2015).  
Emerging technological platforms within the pharmaceutical arena have provided elaborate 
designs and techniques to enhance existing formulations and drug administration routes or to 
accommodate problematic chemical entities (Mehta et al., 2017). The parenteral route is 
beneficial due to direct active delivery into the bloodstream, however, due to poor patient 
compliance and potential anaphylaxis; its regular use for conventional drugs is limited. In 
contrast; pediatric, geriatric or other patient groups with swallowing difficulties (Lopez et al., 
2015a) limit the use of traditional oral dosage forms such as tablets, capsules, and liquids.  
Such dosage formulations also require in depth assessment for in vivo and shelf stability, dosing 
regimen and sustained release. One other crucial aspect relates to dosage form development. 
Although unit operations vary between each form, there is also a need to ensure the correct 
drug content is loaded, and in the case for solid dosage forms, there is limited flexibility for 
patients with allergies or other inhibiting factors (e.g. anatomical or physiological). For these 
reasons, efforts to improve formulation and dosage form design have multiplied over the last 
decade (Lopez et al., 2015a).  
To this end, various formulations have been developed including fast disintegrating tablets, 
lozenges, sublingual tablets and buccal films (Khan et al., 2016). The buccal route for drug 
delivery has generally focused on rapid drug absorption once the dosage form (e.g. film or pill) 
is positioned in the buccal cavity; benefitting from the large volume of sublingual capillaries 
and their proximity to the mucosal layer. Plus, drugs have been shown to enter systemic 
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circulation directly via the jugular vein (Lopez et al., 2015b; Marxen et al., 2016; Thompson 
and DiMartini, 1999; Fonseca-Santos and Chorilli, 2018a). The avoidance of first-pass 
metabolism and intermediate permeation properties makes this an attractive option for pH and 
enzyme sensitive actives (Marxen et al., 2016).  
 
 
Figure 3. 1 Schematic of oral cavity and buccal mucosa histology representative (Fonseca-
Santos and Chorilli, 2018b).  
 
Additionally, the highly vascularized nature of the buccal mucosa offers other added 
advantages (e.g. fast onset of action). Active pharmaceutical ingredients (API's) such as 
nitroglycerin have been developed into sublingual dosage forms (e.g. for the treatment of 
angina) and several types of mucoadhesive formats for buccal delivery have been developed 
including gels, ointments, patches, and tablets e.g. heparin as a gel system (Radivojša 
Matanovic et al., 2015). Finally, rapid cellular recovery is another advantage offered by the 
buccal route (Attia et al., 2004; Salamat-Miller, Chittchang and Johnston, 2005; Boateng and 
Okeke, 2014; Meng-Lund et al., 2014).  
Indomethacin (INDO) belongs to the nonsteroidal anti-inflammatory drug (NSAID) category; 
which is conventionally used to reduce fever, pain, stiffness and swelling. INDO's mode of 
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action is to inhibit production of hormones-like substances (prostaglandins) which cause 
inflammation and pain (Inada et al., 2013). INDO is a hydrophobic drug which is generally 
available in crystalline form. The importance of amorphization is increasing in consequence of 
its value in the pharmaceutical industry for several reasons, including the development of 
poorly soluble active pharmaceutical ingredients and compressibility. Drug amorphization is a 
viable route to enhance solubility and dissolution at the buccal cavity. This in turn has potential 
to increase active bioavailability (Alqurshi et al., 2016).  
In this study, fibrous films for buccal delivery of INDO were formulated and fabricated using 
one-step electrospinning (ESp) technique. The ESp process is an efficient method for 
nanometre and micrometre fibre production using electric fields (~ 15–30 kV) at the ambient 
environment. During the ESp process formulated drug-polymer solutions are stretched into 
filamentous structures arising from electrostatic repulsion between the collecting platform and 
the tip of the formulated media ejecting nozzle (Ahmadipourroudposht et al., 2015). The 
process is suitable to produce composite drug fibres using large and complex molecules, 
without detailed coagulation chemistry, elevated temperature or pressure. Several other 
benefits include facile control on fibre size, shape, and surface charge. Formulation flow rate, 
applied voltage and deposition distance are widely considered as critical factors for fibre 
morphology type whilst material selection significantly affects structure production ability (e.g. 
viscosity, electrical conductivity, surface tension and density)(Haj-Ahmad et al., 2015; Mehta 
et al., 2017). Finally, two further crucial aspects of the ESp process in relation to dosage form 
preparation is the ability to incorporate crystalline actives in the amorphous state (more 
dispersed throughout the filamentous structure) and to control drug volume (width) in resulting 
films through formulation deposition time (Rasekh et al., 2014) providing a route to modulate 
drug content. 
Employing of polymers carriers in modern drug delivery to produce spatiotemporal release of 
therapeutics starts with site specific delivery products and implanted reservoir products. 
Appearance of effective and definite biological therapeutics has intensified the motivation for 
intelligent delivery systems (Liechty et al., 2010).  
Polymer science has advanced the development of several novel drug delivery systems. Surface 
and bulk properties of polymers can help to be designed for numerous drug delivery 
applications. Among them, biodegradable polymer attracts more interest as they can be 
degraded into nontoxic monomer within the body (Pillai and Panchagnula, 2001). On the other 
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hand, blending different polymers with unlike properties could yelled a mixture of striking 
valuable and reasonable way of gaining new structural materials (Bajpai et al., 2008; Yoo et 
al., 2000). Polymer blend advantages over controlled release applications possibly will include 
fabrication of devices, drug loading and enhanced release properties of formulation. Moreover, 
with blend polymer manipulation of the device properties such as hydration, mechanical 
strength and degradation rate can easily be controlled (Bajpai et al., 2008).  
In the current work, amorphous fibrous INDO films were prepared using conventional 
pharmaceutical excipients (Polyvinylpyrolidone (PVP), Ethocel (E10), Methocel (0.5 & E15) 
Hydroxypropyl methyl cellulose (HPMC) and Tween® 80) via single step ESp. Resulting 
fibrous films were evaluated for potential use in buccal delivery with increased amorphous 
drug content and a potential route to control drug volume and patch dimensions in a single step 
at the ambient temperature. 
 
3.2 Aims and objectives 
 
Co-polymer additives could influence the formulation and change the strength of 
intermolecular interaction among the formulation. Therefore, the aim of this chapter is to assess 
the effect of Methocel (0.5 and E15), Ethocel (E10), and HPMC with different concentrations 
(2 and 5% w/v) and Tween 80 with 5% which was added to the formulation with 5% w/v co-
polymer formulations.  
The obtained fibres were analysed by employing thermal analysis using differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA); spectroscopic analysis employing 
Fourier transform infrared (FT-IR) and Raman spectroscopy. The morphology and thickness 
of fibres were examined using Scanning Electron Microscopy (SEM) and atomic force 
microscopy (AFM). The sample preparation method was described in chapter 2. 
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3.3 Materials and methods 
 
3.3.1 Materials 
 
The information related to materials used in this chapter is in chapter 2 (method and materials) 
 
Table 3. 1 Formulated fibres-sample compositions and their drug content. 
Formulation Polymer 
(5%w/v) 
Drug  
(5% w/w) 
Co-polymer 
(w/w) 
Co-polymer 
(5% w/w) 
1 Polyvinylpyrrolidone 
(PVP) 
Indomethacin - - 
2 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Methocel (0.5)                   
2% 
- 
3 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Methocel (0.5)                   
5% 
- 
4 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Ethocel E10                         
2% 
- 
5 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Ethocel E10                         
5% 
- 
6 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Methocel E15                     
2% 
- 
7 Polyvinylpyrrolidone 
(PVP) 
Indomethacin    Methocel E15                     
5% 
- 
8 Polyvinylpyrrolidone 
(PVP) 
Indomethacin     hydroxypropyl 
methylcellulose (HPMC)   
2% 
- 
9 Polyvinylpyrrolidone 
(PVP) 
Indomethacin hydroxypropyl 
methylcellulose (HPMC)   
5% 
- 
10 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Methocel (0.5)                   
5% 
Tween 80 
11 Polyvinylpyrrolidone 
(PVP) 
Indomethacin Ethocel E10                         
5% 
Tween 80 
12 Polyvinylpyrrolidone 
(PVP) 
Indomethacin  Methocel E15                     
5% 
Tween 80 
13 Polyvinylpyrrolidone 
(PVP) 
Indomethacin  hydroxypropyl 
methylcellulose (HPMC)   
5% 
Tween 80 
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3.3.2 Methods 
 
Fibres preparation method is as same as the method mentioned in chapter 2 (methods and 
materials). All preparations contained PVP (5% w/v) and INDO (5% w/w of PVP). Other 
excipients were added in quantities shown in Table 3. 1 as a function of w/w % of PVP.  
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Figure 3. 2 UV-Vis calibration curve of Indomethacin in PBS at ambient temperature 
 
 
 
  
 85 
 
3.4 Results and discussions  
 
Figure 3. 3 shows the surface morphology of formulated electrospun films. Each film sample 
was imaged for plan and horizontal (width) analysis. All fibres exhibit smooth surface 
morphology with evident variation in fibre size distribution between samples. These arise due 
to formulation composition (e.g. co-polymers). Furthermore, the mean fibre diameter was 
found to increase with increasing co-polymer concentration in formulation from  
2% w/v to 5% w/v. Although the percentage of increasing in diameter is different for each co-
polymer. Figure 3. 4 shows diameter size distribution histogram of 100 fibres for each 
formulated system. A clear trend is observed relating to pre-processed formulation media. 
Fibres produced using Methocel (0.5) 2 w/v% (Figure 3. 4A) shows mostly in range of <900 
nm which with increasing the percentage of co-polymer the diameter distribution has increased. 
On the other hand, F10 (5 w/v% + T80) shows the Fibres diameter distribution decreased and 
mostly <300 nm. Fibres produced using Ethocel (E10, 2 w/v%) (Figure 3. 4B) display a narrow 
diameter distribution (all fibres < 300 nm). Fibres produced using Methocel (E15, 2 w/v%) 
(Figure 3C) display a narrow diameter distribution same as formulation with Ethocel E10 (all 
fibres < 300 nm). A broader fibre diameter distribution is observed when using other co-
polymers, especially HPMC 2 w/v% (Figure 3. 4D). A bell-shaped diameter distribution was 
observed for samples F8, F9 and F13.  
Figure 3. 5 shows the side thickness (µm) of formulated electrospun films over predefined time 
(1h). Each film sample was imaged for side measurement analysis. F6 and F9 produced the 
thickest films. F1, F2, F4, F5, F8, F10 and F11 display a thin side diameter of less than 100 
µm. This observation is associated with greater incorporation of drug (INDO) within fibres, 
which accordingly leads to enlarged fibre size (El-Naggar et al., 2016). Figure 3. 6 shows an 
AFM image of randomly selected fibres produced using formulation F5; PVP/INDO/Ethocel 
(E10). Deposited fibres display ribbon-like structures which arise due to two reasons. Firstly, 
the presence of residual solvent in filamentous structures leads to deformation upon contact 
with the collecting surface. Secondly, due to the hygroscopic nature of PVP, moisture 
absorption from the surrounding environment subsequently over time causes change to the 
fibre structure (Rasekh et al., 2014). 
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Figure 3. 3 SEM images of formulated fibres taken at X20K and side image X500 
magnification.  
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 Figure 3. 4 Diameter size distribution histogram of 100 fibers of A (F1, F2, F3 and F10), B (F1, F4, 
F5 and F11), C (F1, F6, F7 and F12), and D (F1, F8, F9 and F13). 
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Figure 3. 5 Diameter size variation of Fibrous films side thickness (µm) 
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Figure 3. 6 AFM image of PVP/INDO/Ethocel (E10) (F5) fibrous films.  
 
DCS thermograms are shown in Figure 3. 7A and Figure 3. 7B. INDO is a crystalline drug with 
a melting temperature (Tm) of 163.5 °C which is shown at ~ 164 °C in Figure 3. 7B. The melting 
temperature of electrospun INDO/PVP films formulated and decreased significantly once 
compared to physical mixtures INDO/PVP, raw INDO and raw PVP. This difference 
corresponds to INDO being molecularly dispersed within the fibrous polymeric films 
increasing the amorphous state of the active. The melting point of electrospun films was higher 
for 2 w/w % polymer and reduced with increasing co-polymer content which might indicate 
increased amounts of polymer in the formulation providing a greater polymeric matrix volume 
for INDO dispersion and spacing. A clear difference is also noted between electrospun fibrous 
films (Figure 3. 7A) and physical mixtures and corresponding raw materials in the formulations 
(5B). Since the physical mixtures do not enable INDO dispersion as efficiently as electrospun 
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films, their melting temperatures are closer to the Tm values of neat drug. The combination of 
INDO, PVP, Ethocel (E10) 5% and Tween® 80 (F11) showed an exothermic peak around 
145.32 °C which is credited to residual solvent entrapped within fibres. 
 
 
Figure 3. 7 DSC thermogram of A. formulated electrospun films B. raw PVP, INDO and 
physical mixture of PVP/INDO.  
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TGA was used to observe the thermal degradation behavior of fibrous films. Earlier studies 
have shown both neat electrospun samples and their drug loaded (INDO) counterparts to 
exhibit similar degradation steps (Taepaiboon, Rungsardthong and Supaphol, 2006). In this 
study, all formulations show two degradation steps; the first is weight loss observed at 
temperatures below 100 °C, which is attributed to the evaporation of the residual solvent or 
adsorbed water in fibrous films, The second major weight loss is observed from 350 to 500 °C, 
which is ascribed to the decomposition of PVP and other co-polymer excipients. 
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Figure 3. 8 TGA curves of formulated electrospun films.  
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TGA thermograms also confirm INDO loading into filamentous matrices. As has been reported 
in a previous study, a shift in the maximum temperature associated with weight loss can be 
used to demonstrate drug entrapment within a fibrous system (Taepaiboon, Rungsardthong and 
Supaphol, 2006). This has been demonstrated using several drugs including INDO, naproxen 
and diclofenac sodium; indicating thermal degradation can be expedited or delayed based on 
the selected active embedded within the fibrous film (Taepaiboon, Rungsardthong and 
Supaphol, 2006). As shown in Figure 3. 8, the maximum thermal degradation values of the 
various formulated drug loaded systems are different from neat INDO and PVP. 
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Figure 3. 9 FTIR spectra of formulated films.  
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Figure 3. 9A shows FTIR spectra for various electrospun samples with different co-polymer 
concentrations in the range 4000–400 cm− 1. The FTIR spectra of samples comprising INDO, 
PVP and other polymers show various characteristic peaks. These are attributed to vibration 
modes of the aromatic ring in INDO (particularly amide νC═O at 1600 cm− 1), various peaks 
of PVP particularly the νC═O at 1680 cm− 1 which shifted to 1654 cm− 1 as a result of hydrogen 
bond formation (Borodko et al., 2006). Other absorption peaks are recorded at 3490 (O―H), 
2983 (C―H), 1920 (C═C) and 1425 cm− 1 (C═C).  
The changes observed in the INDO, PVP and co-polymer sample spectrum exhibit near 
identical peaks as INDO and PVP with a slight change to peak intensity at 1654 cm− 1. This 
arises due to Van der Waals force of attraction or hydrogen bonding between co-polymers. 
New absorption bands were detected in formulations containing co-polymers; apparent at 
1087–1113 cm− 1 and these are attributed to carboxylic acid carbonyl stretching in co-polymers. 
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Figure 3. 10 Raman spectra of formulated films.  
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The FT-Raman spectra of samples comprising INDO, PVP and co-polymers are shown in 
Figure 3. 10. The FT-Raman spectra show a sharp peak at 3080 cm− 1 which indicates O―H 
vibrational stretching of amorphous INDO carboxylic acid group. Other peaks were observed 
at 2884 cm− 1 (ν(C―Η)) and 2220 cm− 1 (ν(C ≅ N)). The peak intensity at 3072 cm− 1 increased 
for all formulations incorporating co-polymers. The increase in peak intensity is due to the 
increasing amorphous INDO content. Furthermore, a new band at 2760–2770 cm− 1 
(corresponding to co-polymers) was observed, suggesting that INDO, PVP and co-polymer 
system were all well integrated as a filamentous structure during ESp. 
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Figure 3. 11 X-ray diffractograms of A. INDO and PVP, B formulated electrospun films.  
 
XRD patterns of formulated electrospun films are displayed in Figure 3. 11. The diffraction 
spectrum of pure INDO powder (Figure 3. 11A) demonstrates that the drug is highly crystalline 
and possesses multiple diffraction peaks at (~ 2 theta = 10–38°). All principle peaks of INDO 
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(11.7, 16.7, 19.5, 21.6 and 21.6) disappeared in the diffractogram of electrospun INDO with 
PVP and various other co-polymers. This indicates INDO is dispersed throughout the fibrous 
matrix and is in the amorphous state. The amorphous state provides several benefits and 
limitations for drug dosage forms. Integrating active in the amorphous state has shown to 
expedite drug release and bioavailability through enhanced solubility. However, this limits 
sustained release features and could also inadvertently result in crystallization and other 
stability issues. 
The drug content in various film dosages ranged between 3 and 4.6% w/w which is less than 
the theoretical maximal value (5% w/w). This may be attributed to drug precipitation. Figure 3. 
12A, B, C and D illustrate the cumulative release profiles for all formulated fibrous samples. 
A reduction in the release rate of INDO was observed by increasing the quantity of water 
insoluble polymer [Ethocel (E10)] from 2% (F4) to 5% (F5) in the formulated systems (Figure 
3. 12B). The effect of ethyl-cellulose content on drug release from polymer beads containing 
INDO has been shown, where increased quantities of the polymer reduce the release rate of the 
active (Suryakusuma and Jun, 1984) (Suryakusuma and Jun 1984). This is explained due to the 
non-soluble nature of the material which limits water interaction with the polymeric matrix. 
The presence of Tween® 80 in samples increased INDO release rate when compared to its 
congener prepared with Ethocel (E10) 5% w/w (F5). Previously it has been shown that the 
solubility of INDO has been increased in the presence of the non-ionic surfactant Tween® 80 
(ATTWOOD et al., 1989). A steep and fast release was recorded for all formulations within 
the first 5 minutes followed by a steady increase. Formulations with co-polymer Methocel 0.5 
(Figure 3. 12A) showed fast release compared to other co-polymers and reached up to 90% of 
their release. On the other hand, formulation with co-polymer Ethocel E10 recorded slower 
release. Moreover, co-polymers Methocel E15 and HPMC indicated that with increasing the 
percentage from 2 w/v% to 5 w/v% release will be decreased Figure 3. 12C and D. The greatest 
release of INDO from fibres (~ 90%) was observed when 2% w/w HPMC was present in 
formulations, whereas a release of only ~ 58% was recorded for its congener with 5% w/w 
HPMC (Figure 3. 12D). A high HPMC polymer concentration results in the formation of a 
viscous gel-like layer which in turn impedes the diffusion of the drug towards the external layer 
and into the test medium. 
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Figure 3. 12 Release profiles of A. F1, F2, F3, F10, B. F1, F4, F5, F11, C. F1, F6, F7, F12, and D. F1, F8, F9, F13 formulations in buffer pH 6.8. 
A1, B1, C1 and D1 show plots of cumulative release against root time for corresponding formulation.     
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The presence of Tween® 80 in fibres prepared with high concentration of HPMC (5% w/w) 
increased the dissolution rate of INDO (~ 62%) (Figure 3. 12D ). The release of INDO from 
fibres containing HPMC exhibited a fast release in the first 5 min followed by a plateauing 
effect until the end of the study. The differences observed in INDO release behavior from fibres 
containing Methocel (0.5), Ethocel (E10), Methocel (E15) and HPMC is attributed to higher 
viscosity of Ethocel (E10) compared to that of Methocel (0.5), Methocel (E15), and HPMC 
resulting in prolonged release of the active over time. Furthermore, the release rate of INDO 
has been modulated previously using ethyl cellulose and HPMC in the formulation (Ohara et 
al., 2005). 
The kinetic release model of PVP/INDO/co-polymer nanofibers is shown in Figure 3. 12A1, B1, 
C1 andD1, in which the cumulative quantity of drug released per square centimeter of fibrous 
films is plotted against time and fitted to the Higuchi model. It was observed that the release 
profile of INDO from fibrous samples of F4 (PVP/INDO/Ethocel (E10) 2%) (R2 = 0.9841) 
suggest that the release of the drug in this formulation is governed by diffusive mechanisms. 
This implies INDO release is based on Fickian diffusion, based on drug permeation through the 
fibrous polymeric network (Neo et al., 2013). 
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3.5 Conclusion  
 
In the current study an array of formulated films containing INDO were fabricated using 
electrospinning (Esp) technology. The drug associated with the fibres was in an amorphous 
state (molecularly dispersed) as evidenced from the X-ray studies whereas the release rate was 
mainly controlled by polymer composition in a sustained manner. The in vitro release of INDO 
was regulated by the quantity and the hydrophilicity/hydrophobicity of Methocel (0.5), 
Methocel (E15), HPMC and ethyl-cellulose in the formulation. The presence of the non-ionic 
surfactant Tween® 80 appears to have a synergistic effect with the polymers depending on their 
amount present in the formulations. The strategy proposed in this study provides a method to 
design novel INDO-polymer hybrid electrospun mats utilized for buccal delivery.  
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Chapter 4 Comparing fast and slow release 
4.1 Introduction 
 
Polymer selection for the design and development of drug dosage forms is as important as the 
nominated active pharmaceutical ingredient (API) (Ting et al., 2016). Formulation and selective 
use of excipients enable specific chemical and physical properties including manufacturing 
method, dosage stability, packaging, handling and bio-interface interactions. A vast variety of 
polymers, from both synthetic and naturally occurring classes, are used for commercial drug 
dosage manufacturing and optimization. Selection is often derived on the basis of material 
suitability when considering engineering steps during product development (e.g. including 
particle or fibre engineering (Hussain et al., 2006; Liechty et al., 2010). 
The buccal route for API administration has gained popularity over the last decade due to 
advances in drug discovery (coupled with potential opportunistic therapies) (Repka, Chen and 
Chan, 2011; Mura et al., 2016), on-demand dosage form development and also to overcome 
disadvantages associated with conventional oral dosage forms (e.g. difficulty swallowing or 
tolerating the enteric route) (Lopez et al., 2015; Nazari et al., 2017). Several methods to develop 
or formulate buccal drug delivery systems have been explored through innovative 
developments in films, patches, tablets and even capsules (Abruzzo et al., 2012). Rapid drug 
absorption (from various dosage form types e.g. pill or film) has been shown in the buccal 
cavity, in addition to greater patient compliance compared with other oral transmucosal 
administration routes (Reddy et al., 2011). Furthermore, greater volume of vascularized tissue 
and blood vessels at this location indicate potential entry into systematic circulation (Pather, 
Rathbone and Senel, 2008), possibly through the jugular vein (Lopez et al., 2015; Reddy et al., 
2011; Marxen et al., 2016). Avoiding drug hydrolysis (often encountered in the gastrointestinal 
tract), enzymatic and acidic action, as well as bypassing first-pass metabolism are all drivers 
for the development of buccal drug delivery systems (Reddy et al., 2011). In terms of 
interactions, a characteristic feature of the buccal mucosa is fast cellular recovery suggesting 
minimal damage to the administration site upon application (Reddy et al., 2011; Attia et al., 
2004; Meng-Lund et al., 2014). The anatomical and physiological property of the buccal region 
leads to high drug bioavailability and fast onset of action. One such active which has been 
explored for buccal delivery is nitroglycerin. The API has been developed into various 
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sublingual dosage forms with notable advances in ointments, gels, film patches and tablets (e.g. 
low molecular weight heparins) (Radivojša Matanovic et al., 2015). 
Several engineering methods have been developed to prepare buccal dosage forms which 
include solvent casting (Palem et al., 2010) and hot melt extrusion. Both methods exhibit 
advantages and limitations during formulation preparation. Electrospinning (ES) is an evolving 
and maturing engineering method with extensive recent interest in the pharmaceutical arena 
(Nazari et al., 2017; Mašek et al., 2017; Bhardwaj and Kundu, 2010). This one-step technique 
has been developed to fabricate fibrous films loaded or co-loaded with API (at required 
quantities in-situ) at the ambient environment (Mehta et al., 2017). Process aspects (applied 
voltage, flow rate and the distance between tip of processing nozzle to collecting platform) and 
pre-formulated material properties (e.g. viscosity, density, electric conductivity and surface 
tension) are often explored and correlated with processing viability (Reneker and Yarin, 2008; 
Jaeger et al., 1998; Tomczak, Van Hulst and Vancso, 2005). ES has numerous sister processes 
namely, electrospraying (Wu and Clark, 2007), EHD printing (J.C. Wang, H. Zheng, M.W. 
Chang, Z. Ahmad, J.S. Li, 2017), microbubbling (Ekemen et al., 2011) and these can be 
complexed further through the use of two or more processing needles (Rasekh et al., 2017). 
NSAID drugs (Indomethacin, Ketoprofen, Diclofenac Sodium and Piroxicom) are non-steroidal 
anti-inflammatory drugs (hydrophobic) are available in crystalline form; which is used for the 
treatment of common illness such as fever, mild to moderate pain, swelling and to relieve 
symptoms of arthritis. NSAID drugs inhibit the production of prostaglandins which are 
responsible for inflammation and pain (Inada et al., 2013; Siddiqui et al., 2014). As a model 
drug, enhancement of NSAID solubility and dissolution at the buccal site requires 
amorphisation. This is crucial and enhances drug bioavailability as its increases molecular 
mobility when compared with the crystalline form (Alqurshi et al., 2016). Numerous studies 
have focused on the development of thin film platforms and the clear majority of these have 
utilised in-vitro or ex-vivo studies for evaluation, although greater bio-interface evaluation is 
needed. Furthermore, assessment using various models (ex-vivo and in-vitro) and how they 
correlate is valuable. 
In the present work, amorphous fibrous of all four drugs (with similar co-polymer addition) 
films were prepared using Polyvinylpyrolidone (PVP) and Ethocel (E10) via single step ES. 
Films were characterised for their size and their components (presence and stability) using 
spectral techniques. Drug loading and encapsulation efficiency of the process was determined. 
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NSAID drugs state was also assessed using XRD analysis and the release behavior of the active 
was explored in vitro (PBS). PBS spreading behavior on engineered polymer films was 
evaluated using surface contact angle measurements.  
 
4.2 Objectives 
 
NSAID drugs are have different physical and chemical properties. Their solubility and 
dissolution rate are different, therefore, could influence the formulation and change the strength 
of intermolecular interaction among the formulations. The aim of this chapter is to assess each 
NSAID drugs in defined formulation from chapter 3 (slow and fast release) and therefore, 
compare the effect of each NSAID drug on the formulation. Furthermore, evaluate co-polymers 
in molecular interaction with new formulated NSAID drugs. This direct us to better 
understanding of NSAID drugs for intended use and preparation by electrospinning technique. 
As a result, evaluate the acceptable NSAID drug for intended use by electrospinning technique.  
The resulting fibres were analysed by employing thermal analysis using differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA); spectroscopic analysis, Fourier 
transform infrared (FT-IR) was employed. The morphology of fibres was examined using 
Scanning Electron Microscopy (SEM). The sample preparation method was described in 
chapter 2. 
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4.3 Materials and methods 
 
4.3.1 Materials 
 
The information related to materials used in this chapter is in chapter 2 (method and materials)  
 
Table 4. 1 Formulated fibres-sample compositions and their drug content. 
Formulation Polymer 
(5%w/v) 
Drug 
(5%w/w) 
Co-polymer 
(5%w/w) 
Drug Content 
(%w/w) 
Sl
o
w
 r
e
le
as
e
 
F1 Polyvinylpyrrolidone (PVP) Diclofenac Sodium Ethocel (E10) 4.86 ± 0.06 
F2 Polyvinylpyrrolidone (PVP) Ketoprofen Ethocel (E10) 3.4 ± 0.12 
F3 Polyvinylpyrrolidone (PVP) Piroxicam Ethocel (E10) 4.06 ± 0.0 
F4 Polyvinylpyrrolidone (PVP) indomethacin Ethocel (E10) 4.8 ± 0.05 
Fa
st
 r
e
le
as
e
 
F5 Polyvinylpyrrolidone (PVP) Diclofenac Sodium - 4.68 ± 0.08 
F6 Polyvinylpyrrolidone (PVP) Ketoprofen - 3.96 ± 0.07 
F7 Polyvinylpyrrolidone (PVP) Piroxicam - 2.43 ± 0.05 
F8 Polyvinylpyrrolidone (PVP) indomethacin - 4.98 ± 0.01 
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4.3.2 Methods 
 
Fibres preparation method is as same as the method mentioned in chapter 2 (methods and 
materials). All preparations contained PVP (5% w/v) and NSAID drugs (5% w/w of PVP). 
Other excipients were added in quantities shown above as a function of w/w % of PVP.  
 
Figure 4. 1 (A) UV-Vis calibration curve (B) UV-Vis spectrometer beam of Diclofenac 
sodium in PBS at ambient temperature 
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Figure 4. 2 (A) UV-Vis calibration curve (B) UV-Vis spectrometer beam of Ketoprofen in 
PBS at ambient temperature 
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Figure 4. 3 (A) UV-Vis calibration curve (B) UV-Vis spectrometer beam of Piroxicam in PBS 
at ambient temperature 
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Figure 4. 4 (A) UV-Vis calibration curve (B) UV-Vis spectrometer beam of indomethacin in 
PBS at ambient temperature. 
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4.4 Results and discussions  
 
Fibrous membranes were engineered using all different NSAID drugs (solution) formulations 
(4 slow release and 4 fast release). Stable jetting was determined using a preliminary applied 
voltage contrasted with infusion rate experimental matrix to ensure near uniform fibre 
engineering. To achieve this stable jetting, several modes are encountered which become 
apparent for various types of media (Arumuganathar, Jayasinghe and Suter, 2007; Jaworek et 
al., 2004) at the nozzle exit. In addition, various jetting modes have been developed based on 
material properties and needle alignment and these have an impact on the end structure 
(Nangrejo et al., 2008; Zhang et al., 2015). However, stable jetting windows were determined 
for NSAID-PVP based formulations and were subsequently used to engineer fibrous films. 
Figure 4. 5 show surface morphology of various electrospun fibrous membranes with inset 
images displaying membrane width (thickness), obtained using plan view microscopic analysis. 
All formulated fibres exhibit a smooth surface; albeit with slightly variable diameter 
distributions. The difference is attributed to the presence of additional co-polymer in the 
formulation (Nazari et al., 2017). Figure 4. 6 shows diameter distributions of 250 randomly 
selected fibres from each electrospun membrane sample. The fibre diameter was noted to 
slightly reduce for most of the formulation upon the inclusion of co-polymer (F6, F7 and F8). 
All formulation displays mean fibre diameters of less than 500 nm. However, formulation 
which cooperated with copolymer not only shows lower fibre dimeter size but also better 
morphology. (Nazari et al., 2017; El-Naggar et al., 2016).  
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Figure 4. 5 Electron microscope of films samples. Comparing fast and slow release 
morphology for each active pharmaceutical ingredient (Slow release; F1 -F4 and fast release; 
F5 – F8) 
 127 
 
 
 
0
50
100
150
200
250
0-250 251-500 501-750 751-1000
N
u
m
b
er
 o
f 
fi
b
re
s
Fiber diameter size range (nm)
F 1
F 4
F1 & F5
0
50
100
150
200
250
300
0-250 251-500 501-750 751-1000
N
u
m
b
er
 o
f 
fi
b
re
s
Fiber diameter size range (nm)
F 2
F 6
F2 & F6
 128 
 
 
 
Figure 4. 6 Fibre diameter size distribution of formulated films. (Comparing both slow and 
fast release formulation for each API). 
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XRD patterns of electrospun fibrous films and neat NSAID drugs are shown in Figure 4. 7. The 
X-ray diffraction pattern of pristine NSAIDs indicate the active possess a highly crystalline 
structure by means of multiple sharp diffraction peaks at (∼2 theta = 10–38°) and principle 
peaks at 11.7, 16.7, 19.5, and 21.6 were observed for indomethacin (Nazari et al., 2017). The 
XRD profile of diclofenac sodium indicate the crystalline nature of this drug as sharp peaks can 
be observed at 11.1, 15.1, and 27.6. Sharp peaks at 5.5, 18.3, and 22.7 in ketoprofen XRD 
profile also indicate the drug crystallinity. Piroxicam XRD profile shows sharp peaks at 8.5, 
14.2, 17.4, and 27.1 which illustrate the crystalline nature of the drug. 
The diffraction spectrum of all electrospun fibrous films (F1–F8) show a diffused background 
pattern with complete disappearance of all principle NSAID drugs peaks. This suggests NSAID 
drugs are well dispersed in fibrous matrices, yielding an amorphous state. The amorphous state 
provides several benefits, including accelerated drug release and enhanced drug solubility, 
which are valuable for bioavailability. However, this must be correlated with permeation 
behavior to gauge real benefit. 
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Figure 4. 7 X-ray diffractograms of (A) raw material and API, (B) formulated film fibres.  
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Figure 4. 8 and Figure 4. 9show DSC and TGA thermograms of electrospun NSAID formulations. 
In its obtained form, NSAID drugs are crystalline and possesses a melting temperature (Tm) of 
∼ 295,100, 209, and 164 °C for Diclofenac sodium, ketoprofen, piroxicam, and indomethacin 
respectively (as shown in Figure 4. 8A). This melting peak is no longer observed for electrospun 
samples, indicating the drug is dispersed throughout the polymer matrix post ES. Numerous 
studies have made use of the ES technique to engineer PVP fibres from the raw polymer (Yu et 
al., 2010; Kamble et al., 2016; Li et al., 2012). In these, a broad endotherm arising at ∼80 °C 
has been reported which also the case in this study for most of the samples which is prepared 
using NSAID and PVP. The broad endotherm at this value is attributed to dehydration which is 
most likely due to loss of moisture often adsorbed by hygroscopic PVP polymer, the rate of 
which may be enhanced due to the increased surface area of fibrous structures. Furthermore, 
cooperation of the ES co-polymer formulation content provides greater polymeric matrix 
volume for active spacing and dispersion. 
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Figure 4. 8 Thermal analyses of A) selected APIs and B) engineered films using differential 
scanning calorimetry. 
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Figure 4. 9 Thermal analyses of A) selected APIs and B) engineered films using Thermal 
gravimetric analysis.  
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TGA was utilized to study thermal degradation behavior of fibrous NSAID-polymer composite 
films. Figure 4. 9 A and B show TGA thermograms of electrospun formulations and raw NSAID 
drugs. In the current study, all fibrous films show two degradation steps (Figure 4. 9B); the first 
relates to weight loss in film formulation below 100 °C, which is ascribed to evaporation of 
residual solvent (ethanol: water) or surface adsorbed moisture on fibrous (and porous) samples. 
The second weight loss step occurs in the range 350–500 °C; and is attributed to degradation 
and decomposition of components comprising fibrous formulations such as PVP and co-
polymer excipients. All C―H, C―N, C═O and C―C bonds are compromised with 
temperatures exceeding 300 °C; after which complete decomposition of PVP into nitrogen and 
carbon oxide powders is observed (Shi, Lu and Jiang, 2009). Previous studies indicate similar 
degradation steps (Taepaiboon, Rungsardthong and Supaphol, 2006). 
TGA thermogram of PVP-NSAID drugs formulations (F1, F3, and F4) shows the highest 
temperature associated with the second weight-loss step when compared with same formulation 
with cooperation of co polymer. On the other hand, formulations F2 and F6 show opposite, as 
same formulation with added copolymer increase the weight-loss step.  
This indicates that incorporation of a co-polymer excipient into the fibrous drug loaded film 
has different effect on the degradation of prepared fibre in respect to NSAID drug. NSAIDs are 
loaded directly into filamentous matrices (Nazari et al., 2017) and previous studies report that 
a shift in the maximum temperature (associated weight-loss step) can be used to validate drug 
entrapment within films (Taepaiboon, Rungsardthong and Supaphol, 2006). The thermal 
degradation of a composite formulation is also driven by the active ingredient (drug) used; as 
both increase and decrease in the maximum temperature associated weight loss have been 
shown (Taepaiboon, Rungsardthong and Supaphol, 2006). 
FTIR spectroscopy was used to study structure and molecular conformation of fibrous films by 
probing band vibrations (Baghel, Cathcart and O'Reilly, 2016). Prepared fibres (PVP-NSAID 
drug) which could be attributed to increased amorphous NSAID drug content. The data suggests 
active drug, base polymer (PVP) and co-polymer (Ethecol™ E10 (where integrated) 
incorporate completely into filamentous structure by ES. 
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Figure 4. 10 Spectroscopic analysis of engineered films and selected excipients using Fourier 
transform infra-red. 
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Figure 4. 10 A and B show FTIR spectra at the wavelength range 4000–400 cm−1. PVP 
background is observed in all samples and various characteristic peaks for other excipients and 
the active are detected. Observed peaks for Indomethacin were amide C═O at 1600 cm−1 which 
is due to vibrations arising from aromatic ring. In addition, absorption peaks are observed at 
2980 and 1423 cm−1 (attributed to C―H vibration of methyl and methylene) (Shi, Lu and Jiang, 
2009) and C═O vibration at 1680 cm−1 from PVP polymer (peaks display weaker intensities at 
∼1661 cm−1) due to hydrogen bonding with the active and other co-polymers (Borodko et al., 
2006). The spectrum of Piroxicam shows absorption bands due to C═O at 1112 cm−1 and OH 
at 3300-3500 cm−1 stretching (Lai et al., 2011). The spectrum of diclofenac sodium shows 
absorption of 3385 cm−1, 1600 cm−1 and 1555 cm−1 due to NH (secondary amine) C═O and 
C═C stretching respectively (Das and Subuddhi, 2015). The spectrum of Ketoprofen shows 
absorption at 1690 and 1655 which attributes to the C═O stretching of carbonyl group (Chan 
et al., 2015). The spectrum exhibits identical for all formulation with slight changes in peak 
intensity due to presence of copolymer in some formulations. This is because of Van der Waals 
forces of attraction or hydrogen bonding in formulation contain copolymer. New peak is 
observed between 1087–1113 cm−1, and is ascribed to carboxylic acid carbonyl stretching 
within copolymer.  
Table 4. 1 represents drug content in fibrous films which is ranged from 2.43 to 4.98% w/w. 
The values are less than the theoretical maxim (5% w/w) incorporated into ES formulations 
prior to processing. This is attributable to drug precipitation during the ES process or shortly 
thereafter. Moreover, sample prepared using copolymer (Ethocel E10) in cooperation with 
Piroxicam reveals greater drug encapsulation compared to formulation without copolymer. 
Other formulations, with adding copolymer (Ethocel E10) the encapsulation show slightly 
reduction. 
Cumulative release profiles of various NSAID formulations are illustrated in Figure 4. 11. The 
presence of Ethocel E10 results in a decrease in API release rate (formulations F1,F2, F3, and 
F4) compared to the single polymer-drug system PVP-NSAID formulations (F5, F6, F7, and 
F8).  
 
 
 137 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100 110 120
%
C
u
m
u
la
ti
ve
 d
ru
g 
re
le
as
e
t (min)
Slow Release
F1
F2
F3
F4
A
0
20
40
60
80
100
120
0 2 4 6 8 10 12
C
u
m
u
la
ti
ve
 p
er
ce
n
ta
ge
 d
ru
g 
re
le
as
e
Square root of time
Slow Release
F1 (R² = 0.9662 )
F2 (R² = 0.7057)
F3 (R² = 0.7812)
F4 (R² = 0.7313)
A1
 138 
 
 
 
Figure 4. 11 Release profiles of A) F1, F2, F3, and F4 (slow release), and B) F5, F6, F7 and 
F8 (fast release) formulations in buffer pH 6.8. A1 and B1 show plots of cumulative release 
against root time for corresponding formulation.     
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A reduction in the release rate of NSAID drugs were observed by adding water insoluble 
polymer (Ethocel (E10)) (F1, F2, F3, and F4) in the formulated systems Figure 4. 11A. The effect 
of ethyl-cellulose content on drug release from polymer beads containing NSAID drugs has 
been shown, that with adding co-polymer the release rate has reduced. This is explained due to 
the non-soluble nature of the material which limits water interaction with the polymeric matrix. 
Slow release formulations group (F1, F2, F3, and F4) show a steep and fast release within first 
5 mins followed by a steady increase up to 12% for F1, 43% for F2, 29% for F3, and 91% for 
F4. NSAID drugs show different characteristic and therefore each present different release 
profile.   
Fast release formulations group (F5, F6, F7, and F8) show a sharp and fast release within the 
first 5 min followed by a steady increase. However, the release rate was different for each 
formulation. F8 shows the highest release rate and with a steady rate up to 91%. F5 and F7 
show the lowest release at about 12%. F6 shows a steep and fast followed by a steady release 
up to 43%.  
The kinetic release model of PVP/NSAID/co-polymer nanofibers is shown in Figure 4. 11A1 
and B1, in which the cumulative quantity of drug released per square centimeter of fibrous films 
is plotted against time and fitted to the Higuchi model. Drug release from all formulations 
showed two distinct release phases; an initial burst type release phase followed by a lag period. 
It was observed that the release profile of NSAID drugs from fibrous samples of F1 
(R2 = 0.9662), F2 (R2 = 0.7057), F3 (R2 = 0.7812), F4 (R2 = 0.7313), F5 (R2 = 0.5096), F6 
(R2 = 0.5439), F7 (R2 = 0.4949), and F8 (R2 = 0.4067) suggest that the release of the drug in this 
formulation is governed by diffusive mechanisms. This implies NSAID release is based on 
Fickian diffusion, based on drug permeation through the fibrous polymeric network.  
Higuchi kinetic model fitting was applied to the initial phase. All slow release formulations 
show high linearity with R2 (>0.7). It can be concluded that the dominating mechanism for 
NSAID drug release is Fickian diffusion. However, the release rate is different for 
each formulation; where F possessed the greatest K value and F5 possessed the lowest K value. 
 
4.5 Conclusion  
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In the current study an array of formulated films containing NSAID drugs were fabricated using 
electrospinning ES technology. The nanofibers showed consistent fibre morphology, which 
would improve the release of drug from matrix to the skin due to large surface area. However, 
some of the electrospun formulations showed beading within the nanofibres, and therefore the 
formulation requires further optimizations for each of APIs and incorporated polymer/co-
polymer. 
The drug associated with the fibres was in an amorphous state (molecularly dispersed) as 
evidenced from the X-ray studies whereas the release rate was mainly controlled by polymer 
composition in a sustained manner. The in vitro release of NSAID were regulated by the 
quantity and the hydrophilicity/hydrophobicity ethyl-cellulose in the formulation. The strategy 
proposed in this study provides a method to design novel NSAID-polymer hybrid electrospun 
mats utilized for buccal delivery. 
By using this technique, it has been proved that NSAID drugs can be encapsulated in polymeric 
nanofibres matrix in order to achieve the amorphous state of drug for buccal drug delivery. 
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Chapter 5 Comparing Electrospinning films with Casting films 
5.1 Introduction 
 
Pharmaceutical industry has put a large amount of efforts into the actives that work on new 
technologies, to tackle problems associated with drug administration and drug delivery system 
which is effective stage to progress pharmaceutical and therapeutics of drug. These systems 
help drugs to overcome barriers which are associated with actives, such as low solubility due 
to the nature of drug hydrophobicity, and therefore prevent degradation of drug prior to reach 
the target area (Santos et al., 2018; Allen and Cullis, 2004). Many systems and devises have 
attracted attention for oral cavity application and absorption as oral cavity provide a large 
surface area for drug absorption (Prausnitz, Mitragotri and Langer, 2004). Transdermal delivery 
developed successfully in past years and has gained approval for many drugs (Santos et al., 
2018; Wiedersberg and Guy, 2014). It is a reliable alternative to the oral route, both for local 
and for systemic delivery of drugs, overcoming some of the drawbacks existent in oral 
administration, avoids the first-pass effect, pre-systemic elimination by the gastrointestinal 
tract, adverse drug reactions and moreover, provide a fast absorption of drug (Santos et al., 
2018; Naik, Kalia and Guy, 2000). The buccal route for drug administration has gained 
importance in the past years due to its accessibility and rapid onset of action. It is a reliable 
alternative to the oral route, both for local and for systemic delivery of drugs. 
The buccal route of administration is a specific type of drug delivery that involves the patient 
placing the drug in the gap between the gum and the cheek until it completely dissolves. During 
this time, the active pharmaceutical ingredient (API) will penetrate from the drug formulation 
into the bloodstream through the tissue lining of the mouth, or oral mucosa, via diffusion. 
The buccal route enhances absorption of poorly absorbable drug and providing an effective 
drug delivery (Sudhakar, Kuotsu and Bandyopadhyay, 2006; Al-Dhubiab et al., 2015). Buccal 
delivery system attracted many scientists because can be developed in such as a reservoir for 
sustain release systems (Al-Dhubiab et al., 2015; Downing et al., 2014).  
Many methods have been developed to prepare buccal dosage forms which include solvent 
casting (Palem et al., 2010) and hot melt extrusion (HME) (Morales and McConville, 2011). Currently 
under research however, is the formulation of buccal films by making drug-loaded fibres via 
electrospinning.  
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Figure 5. 1 Contact stage and drug permeation from buccal film 
 
Solvent film casting is a very simple and cost-effective method, whereby the drug and 
excipients are dissolved into a solution, usually with a mixture of water and another suitable 
solvent for non-water-soluble excipients such as ethanol. This forms a viscous solution, 
allowing it to be spread across (casted) on a surface with more control. The solution is then left 
to dry into a film, after which can be collected and manufactured into its desired product 
formulation (Morales and McConville, 2011; Karki et al., 2016; Barnhart, 2008).  
The HME is a process that requires much more sophisticated equipment, software and requires 
sufficient training for operation of the equipment. However, this method is a continuous process 
that provides better content uniformity and less unit operations are needed when compared to 
solvent film casting. The process involves mixing the drug and its carriers in their dry state as 
the first step. Once mixed, the mixture is inputted into the HME hopper and passed through its 
heating chambers to undergo melting. The melt is then extruded into a die, which will shape 
the melt into a film, after which it can be left to cool and dry for collection (Repka et al., 2007; 
Morales and McConville, 2011). 
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The effectiveness of the drug delivery profile of buccal formulations vastly depends on the 
mucoadhesive properties of the formulation. Mucoadhesion, in pharmaceutical terms for buccal 
administration, is the two-part mechanism that describes the attractive interaction between the 
components of the formulation and the mucous membrane of the buccal region. The first part 
is known as the Contact Stage – which is the time of intimate contact between the buccal 
mucous membrane and the mucoadhesive buccal formulation. The second stage is the 
Consolidation Stage – this involves the drug and its mucoadhesive carriers penetrating either 
into the oral mucosa membrane or into the crevices of tissue in the buccal area (Smart, 2004; 
Morales and McConville, 2011; Smart, 2005). This two-part description is essential, as the 
ability of the drug and its carriers to penetrate the mucus layer will determine the how 
effectively the drug particles will be transported into the bloodstream and ultimately decides 
the overall therapeutic effect (Guo, 1994; Morales and McConville, 2011). Therefore, it is of 
great importance that the mucoadhesive properties of the formulation is properly characterised 
and understood through testing. 
Both methods exhibit advantages and limitations during formulation preparation. 
Electrospinning (ES) is an evolving and maturing engineering method with extensive recent 
interest in the pharmaceutical arena (Nazari et al., 2017; Mašek et al., 2017; Bhardwaj and 
Kundu, 2010; Mehta et al., 2017). This one-step technique has been developed to fabricate 
fibrous films loaded or co-loaded with API (at required quantities in-situ) at the ambient 
environment (Mehta et al., 2017).  
Currently available rapid disintegrating buccal formulations such as tablets and patches have 
limitations relating to the short residence time at the absorption surface (Madhav et al., 2009; 
Al-Dhubiab et al., 2015). Here electrospinning films and cast films were proposed to assess 
their physical, chemical structure, and potential to release the molecule for prolonged period of 
proposed time (Salamat-Miller, Chittchang and Johnston, 2005; Al-Dhubiab et al., 2015; Dixit 
and Puthli, 2009). Therefore, the development of drug-loaded nanofibers may can overcome 
this problem by enhancing the surface area for interaction based on grooves and total surface 
exposure.  
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5.2 Aims and Objectives 
 
The aim of this study was to investigate the effect of the technology on the film preparation. 
Electrospinning and cast method were carried out. Prepared films were analysed to determine 
their structure, morphology, thermal, and chemical properties of produced films.   
Formulation system could influence the bioavailability, permeability and residential time of 
drug. Therefore, the aim of this chapter is to assess the films prepared by electrospinning and 
cast process.  
The result fibre and cast films were analysed by employing thermal analysis using differential 
scanning calorimetry (DSC) and thermogravimetric analysis (TGA); spectroscopic analysis 
employing Fourier transform infrared (FT-IR) and Raman spectroscopy. The morphology of 
fibres and cast were examined using Scanning Electron Microscopy (SEM). The sample 
preparation method was described in chapter 2. 
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5.3 Materials and methods 
 
5.3.1 Materials 
 
The information related to materials used in this chapter is in chapter 2 (method and 
materials) 
 
Table 5. 1 Formulated fibres-sample compositions and their drug content. 
Formulation Polymer 
(5%w/v) 
Drug 
(5%w/w) 
Co-polymers 
(%w/w) 
 Drug 
Content 
(%w/w) 
El
e
ct
ro
sp
in
n
in
g
 
F1 Polyvinylpyrrolidone 
(PVP) 
indomethacin - -  
4.98 ± 0.01 
F2 Polyvinylpyrrolidone 
(PVP) 
indomethacin Ethocel (E10) 
(5%) 
-  
4.8 ± 0.05 
F3 Polyvinylpyrrolidone 
(PVP) 
indomethacin Ethocel (E10) 
(5%) 
Tween 
80 
 
3.4 ± 0.21 
C
as
t 
F4 Polyvinylpyrrolidone 
(PVP) 
indomethacin - -  
4.98 ± 0.02 
F5 Polyvinylpyrrolidone 
(PVP) 
indomethacin Ethocel (E10) 
(5%) 
-  
4.94 ± 0.03 
F6 Polyvinylpyrrolidone 
(PVP) 
indomethacin Ethocel (E10) 
(5%) 
Tween 
80 
 
4.92 ± 0.02 
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5.3.2 Methods 
 
Fibres and cast preparation methods is as same as the method mentioned in chapter 2 (methods 
and materials). All preparations contained PVP (5% w/v) and INDO (5% w/w of PVP). Other 
excipients were added in quantities shown in Table 5. 1 as a function of w/w % of PVP.  
 
 
Figure 5. 2 Digital image of prepared cast (left) and fibre (right) 
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5.4 Results and discussions  
 
Figure 5. 3 SEM images of formulated fibres taken at X25K and cast image X5K magnification.shows 
digital image of surface morphology of formulated electrospun and cast films. All fibres exhibit 
smooth surface morphology with evident variation in fibre size and quality distribution between 
samples. F1 shows more bubble like in the fibre compare to others (F2 and F3). These arise due 
to formulation composition (e.g. co-polymers). Furthermore, the mean fibre diameter was found 
to increase with adding co-polymers to the formulation. Fibers produced using Ethocel (E10) 5 
w/w % showed slightly increase in diameter, although mostly less than 300nm. On the other 
hand, formulated fiber with added second co-polymer (Tween 80) presented mostly in range 
300-600nm (Figure 5. 4). 
 
 
Figure 5. 3 SEM images of formulated fibres taken at X25K and cast image X5K 
magnification.  
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Figure 5. 4 Diameter size distribution histogram of 100 fibers of F1, F2, and F3. 
 
 
DSC is one of the thermal analytical technique which allows for direct study of thermal stability 
of drugs. Heat flow between a sample and an inert reference sample during a specified 
temperature is monitored. DCS thermograms are shown in Figure 5. 5 (A and B). INDO is a 
crystalline drug with a melting temperature (Tm) of 163.5 °C which is shown at ~ 164 °C in 
chapter 3. 
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Figure 5. 5 DSC thermogram of A) formulated electrospun films and B) formulated cast 
films. 
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The melting temperature of formulated INDO/PVP electrospun films decreased significantly 
once compared to raw INDO, raw PVP and physical mixture of INDO/PVP (chapter 1). This 
difference corresponds to INDO being molecularly dispersed within the fibrous polymeric films 
increasing the amorphous state of the active. The melting point of electrospun films was higher 
for INDO/PVP polymer and reduced with increasing co-polymer content which might indicate 
increased amounts of polymer in the formulation providing a greater polymeric matrix volume 
for INDO dispersion and spacing.  
A clear alteration is also noted between electrospun fibrous films Figure 5. 5 (A and B) and cast 
films and the corresponding raw materials in the formulations. Since the cast do not enable 
INDO dispersion as efficiently as electrospun films, their melting temperatures are closer to the 
Tm values of neat drug. The combination of INDO, PVP and Ethocel (E10) 5% (F2) and INDO, 
PVP, Ethocel (E10) 5% and Tween® 80 (F3) showed an exothermic peak around 160 °C and 
145.32 °C respectively, which is credited to residual solvent entrapped within fibres. Though 
the insensitivity of exothermic is slightly higher for F3 formulation. 
 
TGA is another thermos analysis technique which provides very useful and relevant 
information for materials of interest by measuring and recording melting point, transition 
temperature and weight loss of materials. TGA was employed to observe the thermal 
degradation of electrospun and cast films. The previous studies (chapter 1-4) have shown both 
neat electrospun samples and their drug loaded (INDO) counterparts to exhibit similar 
degradation steps.  
All formulations (electrospun) show two degradation steps; the first is weight loss observed at 
temperatures below 100 °C, which is attributed to the evaporation of the residual solvent or 
adsorbed water in fibrous films. The second major weight loss is observed from 350 to 
500 °C, which is ascribed to the decomposition of PVP and other co-polymer excipients. 
However, electrospun formulations with co-polymer (F2 and F3) show earlier degradation 
compare to F1. 
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Figure 5. 6 TGA curves of A) formulated electrospun films and B) formulated cast films. 
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TGA thermograms also confirm INDO loading into filamentous matrices. As has been 
reported in a previous study, a shift in the maximum temperature associated with weight loss 
can be used to demonstrate drug entrapment within a fibrous system. This is indicating 
thermal degradation can be expedited or delayed based on the selected active or co-polymers 
embedded within the fibrous film. As shown in Figure 5. 6, the maximum thermal degradation 
values of the various drug loaded systems are different from neat INDO and PVP (chapter 3). 
Figure 5. 7 (A and B) shows FTIR spectra for F1, F2, and F3 electrospun samples and F4, F5, 
and F6 Cast samples with different co-polymer concentrations in the range 4000–400 cm− 1 
respectfully. The FTIR spectra of samples comprising INDO, PVP and other polymers show 
various characteristic peaks. These are attributed to vibration modes of the aromatic ring in 
INDO (particularly amide νC═O at 1600 cm− 1), various peaks of PVP particularly the νC═O 
at 1680 cm− 1 which shifted to 1654 cm− 1 as a result of hydrogen bond formation (Borodko et 
al., 2006). Other absorption peaks are recorded at 3490 (O―H), 2983 (C―H), 1920 (C═C) and 
1425 cm− 1 (C═C).  
The changes observed in the INDO, PVP and co-polymer sample spectrum exhibit near 
identical peaks as INDO and PVP with a slight change to peak intensity at 1654 cm− 1. This 
arises due to Van der Waals force of attraction or hydrogen bonding between co-polymers. New 
absorption bands were detected in formulations containing co-polymers; apparent at 1087–
1113 cm− 1 and these are attributed to carboxylic acid carbonyl stretching in co-polymers. 
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Figure 5. 7 FTIR spectra of formulated A) fibre films and B) casts.  
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XRD patterns of formulated electrospun films and cast films are displayed in Figure 5. 8. The 
diffraction spectrum of pure INDO powder (Figure 5. 8A) demonstrates that the drug is highly 
crystalline and possesses multiple diffraction peaks at (~ 2 theta = 10–38°) whereas, PVP shows 
a broad amorphous band. All principle peaks of INDO (11.7, 16.7, 19.5, 21.6 and 21.6) 
disappeared in the diffractogram of electrospun INDO with PVP and various other co-polymers. 
This indicates INDO is dispersed throughout the fibrous matrix and is in the amorphous state.  
On the other hand, all cast formulations show peaks at 29, 32, and 38 (Figure 5. 8C). This indicate 
the crystallinity of cast prepared formulations.  
The amorphous state provides several benefits and limitations for drug dosage forms. 
Integrating active in the amorphous state has shown to expedite drug release and bioavailability 
through enhanced solubility. However, this limits sustained release features and could also 
inadvertently result in crystallization and other stability issues. 
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Figure 5. 8 X-ray diffractograms of A) INDO and PVP, B) formulated electrospun films, and 
C) formulated casts.  
 
0
10
20
30
40
50
60
70
80
90
5 10 15 20 25 30 35 40
In
te
n
ci
ty
 (
a.
u
.)
2Theta
F4
F5
F6
C
0
5
10
15
20
25
5 10 15 20 25 30 35 40
In
te
n
ci
ty
 (
a.
u
.)
2Theta
F1
F2
F3
B
 159 
 
The drug content in various film dosages ranged between 3.4 and 4.9% w/w which is less than 
the theoretical maximal value (5% w/w). This may be attributed to drug precipitation. Figure 5. 
9 illustrate the cumulative release profiles for all formulated fibrous samples and cast samples 
respectively. A reduction in the release rate of INDO was observed by adding water insoluble 
polymer (Ethocel (E10)) in the formulated systems (Figure 5. 9). The effect of ethyl-cellulose 
content on drug release from polymer beads containing INDO has been shown, where polymer 
cause reduction in the release rate of the active (Suryakusuma and Jun, 1984) (Suryakusuma 
and Jun 1984). This is explained due to the non-soluble nature of the material which limits 
water interaction with the polymeric matrix. The presence of Tween® 80 in samples reduced 
the release rate further when compared to its congener prepared with Ethocel (E10) 5% w/w. A 
steep and fast release was recorded for all formulations within the first 5 minutes followed by 
a steady increase. Formulations (F1 and F2) showed faster release compare to F3 and reached 
up to 90% of their release. However, F3 release reached up to 70%.  
 On the other hand, cast formulations recorded slower release compare to same formulation in 
electrospun form. The greatest release of INDO from casts (~ 90%) was observed for 
formulations F4 and F5. F6 recorded about 70% of release. The variation release profile of 
formulation is due to attribution of higher viscosity of Ethocel (E10) compared to the 
formulations with no co-polymer and therefore, resulting in prolonged release of the active over 
time. 
The kinetic release model of PVP/INDO/co-polymer nanofibers and cast are shown in Figure 5. 
9  where the cumulative quantity of drug released per square centimeter of fibrous films is 
plotted against time and fitted to the Higuchi model. It was observed that the release profile of 
INDO from fibrous sample F3(R2 = 0.9648), F4 (R2 = 0.9522), F5 (R2 = 0.9515), and F6 
(R2 = 0.939), suggest that the release of the drug in these formulations were governed by 
diffusive mechanisms. This implies INDO release is based on Fickian diffusion, based on drug 
permeation through the fibrous polymeric network (Neo et al., 2013). 
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Figure 5. 9 Release profiles of A) F1, F2, F3, and B) F4, F5, F6 formulations in buffer pH 6.8. 
A1 and B1 show plots of cumulative release against root time for corresponding formulation.     
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5.5 Conclusion 
 
The buccal route of administration is a specific type of drug delivery that involves the patient 
placing the drug in the gap between the gum and the cheek until it completely dissolves. It is a 
promising administration route since it avoids destruction from the gastro-intestinal tract and 
first-pass metabolism by the liver, thereby providing better bioavailability with less wastage 
and possible harmful intermediates being produced from these reactions. It as an alternative to 
other delivery system such as nasal or skin. Penetration of active pharmaceutical ingredient 
(API) is with ease due to physiology of the buccal mucosa. Moreover, it has rapid cellular 
turnover and recovery. Also, film casting, and hot melt extrusion has been successfully explored 
for mucoadhesive buccal films but still many possibilities stay in the design of buccal films. 
Currently under research however, is the formulation of buccal films by making drug-loaded 
fibres via electrospinning. However, preceding aim of pharmaceutical scientists with new 
improving technology is to manufacture patient safe and friendly dosage form.  
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Chapter 6 Quality by design of Nano-pharmaceutical fibres 
6.1 Introduction 
 
Quality by Design (QbD) is a statistical analytical tool that uses sound science and risk-based 
knowledge to approach experiments and projects with the goal of achieving a product that can 
be consistently manufactured to its desired level of safety, efficacy and quality. Therefore, 
adequate control is required to assure the manufacturing process is performed to a high level 
of accuracy, robustness and reliability. In recent years, the pharmaceutical industry has 
highlighted, risk management and quality by design (QbD) as the importance of product 
quality has elevated. With application of nanotechnology and nanomaterials to drugs, massive 
improvement in health challenges such as bioavailability, biodistribution, drug action, 
degradation and targeted delivery area has been achieved. However, there will be risks 
associated with formulation and the materials used and therefore, the need for an approach to 
address them is necessary. QbD prevents alteration of quality and safety of new formulation 
or new drug by identifying, analysing and control all parameters that might affect the process 
(Bastogne, 2017; Pramod et al., 2016; Colombo et al., 2018).  
Important QbD objectives in pharmaceutical are as: a) consistent production of high quality 
products by design the processes and manufacturing, b) identification and control process 
parameters and important component to determine the critical quality attributes (CQAs), c) 
reduce the deviation to improve process capability and d) to tackle the cause of problems and 
manage changes after approval. (Yu et al., 2014; Yerlikaya et al., 2013; Ko et al., 2018; Pramod 
et al., 2016). Process design is the key focus of the QbD. Risk based approach and the relation 
with QbD has been discussed in ICH Q8, Q9, and Q10 (Ko et al., 2018; Thakur, Kaur and 
Sharma, 2017; Hubert et al., 2014a; International Conference on Harmonization (ICH), 2009a; 
International Conference on Harmonization (ICH), 2009b; International Conference on 
Harmonization (ICH), 2008) 
Quality by Design (QbD) is a risk-based tool used by many pharmaceutical industries with the 
goal of ensuring the quality of the final product by improving product and process 
understanding (Sangshetti et al., 2017a). This is because a better understanding will enable 
better process control to be achieved (Rathore and Winkle, 2009; Bastogne, 2017). When good 
process control has been established, the manufacturing process will become more robust, 
efficient and cost effective, all while reducing the variability in quality during all manufacturing 
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stages, which will ultimately guarantee the end product quality (Yu et al., 2014; Ko et al., 2018; 
Wu and Khan, 2009; Stults et al., 2015; Rahman, Siddiqui and Khan, 2013).  
The foundations (green), stages (red chevrons) and enablers (yellow) of a QbD approach are 
summarised in Figure 6. 1. It emphasises the importance of using prior knowledge (knowledge 
already known about the process/product) alongside the new understanding of the process and 
product through a risk-based approach to form the foundations (Vogt and Kord, 2011; Rozet et 
al., 2013).  
 
Figure 6. 1 Roadmap and stages of QbD  
 
The use of Process Analytical Technique (PAT) tools helps to further enhance QbD elements 
in experiments. PAT tools are convenient instruments that can be used to take measurements, 
whether in-line, at-line, on-line or off-line (Sangshetti et al., 2017b). Statistical software 
programmes, such as JMP, can also be used as a PAT tool, which is capable of performing 
multivariate analysis, which involves assessing how multiple parameters can affect the 
responses of interest (the variables or characteristics that can greatly affect the product quality) 
simultaneously. PAT can aid in gaining information that may be applied towards modelling of 
the process, further improving process understanding. A Design of Experiment (DoE) can be 
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constructed, which is a pre-planned experimental design that aims to describe the relationships 
of the input variables, process parameters and the responses (output variables). The number of 
runs required to perform the experiment depends on what design is used to make the DoE, how 
many independent factors are being assessed and the number of centre points included in the 
design. Centre points allow curvature to be recorded in the results, which helps to further 
understand the relationship between the factors and responses (Dispas et al., 2018; Hubert et 
al., 2014b). 
The stages of the QbD process are outlined in the chevrons in Figure 6. 1. The first stage is to 
create a Quality Target Product Profile (QTPP), which is essential for a QbD approach as stated 
in the ICH Q8 (International Conference on Harmonization (ICH), 2009a). The QTPP defines 
the requirements of the end product characteristics and which of these are critical to 
manufacturing the product to its required efficacy, safety and quality so that the patient may be 
satisfied with the product. Therefore, the QTPP serves as a collection of properties and their 
acceptable ranges/values of a model product for the pharmaceutical chemists to target 
(Sangshetti et al., 2017a; Zhang and Mao, 2017).  
The Critical Quality Attributes (CQAs) are the physical, chemical, biological and 
microbiological properties of the product and its intermediates that are considered to have 
potential to greatly affect the quality of the final product (e.g. electro conductivity, surface 
tension). Therefore, it is of paramount importance to consistently monitor and control these 
CQAs. Critical Material Attributes (CMAs) also link in with CQAs and are defined as the 
physical, chemical, biological and microbiological properties of the input materials used in the 
experiment (e.g. polymer molecular weight). These CQAs can be identified by studying the 
QTPP in conjunction with performing risk assessments. Risk assessments can be done by 
providing risk scores through a traffic light system or Ishikawa diagram (Figure 6. 3). 
Critical Process Parameters (CPPs) are the parameters of the process (e.g. flow rate, voltage) 
that are critical to the final product quality. As with CQAs, they can be identified through risk 
assessments, such as a traffic light system of CQAs against CPPs. They also need to be well 
controlled and monitored throughout the process, as this helps to control the CQAs too. PAT 
tools can aid in the control of parameters so that the CQAs can be maintained within their 
critical limits. This can work by the tool alerting the operator that a particular parameter or 
CQA is outside of its limits, enabling the operator to manually change the parameter to its 
appropriate settings (Zhang and Mao, 2017). Another way is that the PAT tool could be set up 
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so that it can monitor the parameters and relevant CQAs and automatically feedback or 
feedforward the information, via proportional, integral and derivative (PID) control, to allow 
the system to ‘fix itself’ if a parameter or CQA is outside of its pre-determined limits. 
The design space is defined as the multidimensional space (space created by the relationships 
between multiple variables), where working within this space is not considered a change and 
the parameters and CQAs are within limits to ensure its desired quality levels are met. Although 
a design space is optional, its benefits are certainly invaluable and offers a range of choices that 
can be chosen to suit the operator’s need. A design space cannot be created until results have 
been obtained. This is because sufficient knowledge is required to create the design space, as 
shown in Figure 6. 2, where the design space is within the knowledge space. If part of the design 
space is outside the knowledge space, then there will be some grey areas where there is poor 
understanding about a particular aspect of the process or product, and so further testing would 
be required to gain more knowledge about this. The normal operating space is the space in 
which the operator has decided to work within, while still inside the design space. This 
particular space may be chosen to further guarantee the quality of the product or it may be that 
these parameter limits offer more efficient and cost-effective settings whilst maintaining the 
end product quality (Sangshetti et al., 2017a). The design space can be demonstrated in different 
forms, also a 3D response surface plot can give more information about the relationship 
between the variables, while a 2D contour plot can give straightforward detail on the variable 
settings that will be within the design space. 
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Figure 6. 2 Different spaces associated with the design space  
 
With all of the above information obtained, a control strategy can then be devised. This is a 
planned set of controls taken from current process and product understanding to further ensure 
the process performance and product quality is of appropriate standards. The control elements 
involve, but not limited to, input controls, process controls, and testing controls of unit 
operations and CQAs of the product. This is an essential part of QbD that helps to summarise 
the controls that must be established during the manufacturing process (Sangshetti et al., 
2017b). 
Continuous improvement is the final stage, which can go on for as long as is necessary. This is 
because the process can be improved in future to promote cost-effectiveness, efficiency, 
robustness, time saving changes and product quality by periodically reviewing and assessing 
the process and product understanding, the. Also, new technological advancements will be 
developed that may be applicable to the manufacturing process of interest (Zhang and Mao, 
2017).  
Nevertheless, a very small number of studies have been conducted where Quality by Design 
(QbD) have been incorporated in the experiments of researches involving electrospinning. 
Therefore, in order to obtain better process and product understanding, QbD is required to be 
included in electrospinning projects. 
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6.2 Aims and objectives 
 
The aim of this project is to apply the concepts of QbD to the electrospinning of NSAID drugs 
and determine and control the most significant factors that can affect the quality of the fibre. 
Creating a design space and control strategy for the process is also a target to be achieved.  
The objectives of this chapter are: 
• To construct a Quality Target Product Profile (QTPP) 
• Perform Risk Assessments to identify Critical Quality Attributes (CQAs) and Critical 
Process Parameters (CPPs) 
• Construct a Design of Experiment (DoE), where the factors to be assessed that can affect 
the product quality are: Flow rate, voltage, distance between electrospinning needle and 
collector and drug used in formulation; and the responses to monitor are: fibre diameter, 
fibre quality and drug release profiles  
• Perform the experiments and obtain results 
• Analyse results and use statistical analytical software to develop a design space and 
create a control strategy 
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6.3 materials and methods 
 
6.3.1 Materials 
 
The materials that will be used in the proposed experiment are shown in Table 6. 1. 
Table 6. 1 Formulated fibres-sample compositions and their drug content. 
Formulation Polymer Drug Drug Content (w/w 
%) 
F1 Polyvinylpyrrolidone (PVP) Diclofenac Sodium 4.68 ± 0.08 
F2 Polyvinylpyrrolidone (PVP) indomethacin 4.98 ± 0.01 
 
 
6.3.2 Methods 
 
Fibres preparation method is as same as the method mentioned in chapter 2 (methods and 
materials). All preparations contained PVP (5% w/v) and NSAID drugs (Indomethacin and 
Diclofenac Sodium) (5% w/w of PVP).  
A full factorial Design of Experiment (DoE) was made with four factors at 2 levels each, two 
responses and four center points. Therefore, a total of 20 runs were performed, where each run 
was done for 1 hour. The details of the DoE dialog are shown in Table 6. 2. 
Table 6. 2 Factorial Design of Experiment (DoE) dialog  
DoE Component Response or 
Factor 
Lower limit Upper limit Centre Point 
dimensions 
Fibre Diameter / nm Response None <1000nm N/A 
Quality of Fibre Response 1 5 N/A 
Drug (Indomethacin and 
Diclofenac Sodium) 
Factor 5% of 
formulation 
5% of 
formulation 
Two centre points 
for each drug 
Voltage / kV Factor 10 20 15 
Flow Rate / µl/min Factor 5 35 20 
Distance between needle 
and collector / cm 
Factor 5 20 12.5 
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6.4 Applying QbD 
 
Prior to the proposed methodology, the initial applications of QbD must first be made. 
 
6.4.1 The QTPP-intent design 
 
Since a complete product will not be manufactured, the design intent of a QTPP was made, as 
shown in Table 6. 3. Here, a description of the quality attributes of the materials and product is 
given, along with their intended target limits and purpose and the level of criticality on how 
greatly they may affect the final product quality. From this, the primary CQAs that will be 
monitored are: fibre diameter, fibre quality and release profile. 
Table 6. 3 Design intent of QTPP describing the criticality levels of the attributes that may 
affect the quality of end product. 
Quality attribute Target Criticality 
Product Form Fiber Critical 
Fibre Diameter ≤ 2µm to maximise surface area Critical 
Release Profile Slow or fast release (depend on intended use) Critical 
Fibre Quality Structure and shape must be consistent throughout fiber Critical 
Impurities Must be low as possible to avoid harm/instability Not Critical 
Pharmacokinetics Must be appropriate Not Critical 
Solubility Should be reasonable Not Critical 
Microbiology Must be low and within limits Not Critical 
Stability Must have consistent stability profile Critical 
Porosity Must have high porosity to maximize surface area Critical 
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6.5 Risk assessments  
 
The initial risk assessment (RA) of the CQAs against the formulation variables of the process 
before applying controlled factors are fibres quality, fibres diameter, and release study. It 
becomes clear that most of the variables pose high risks towards the CQAs. Therefore, some of 
the variables require to be controlled to avoid results being impacted. 
During the experiment all parameter kept constant and thereafter, the risk factors such as fibres 
quality, fibres diameter, and release study which are the main risk consideration of the CQAs 
against the formulation variables need to be evaluated.  
It is evident that this greatly lowers the overall risk as the drug used will be part of the 
experiment and so will be deliberately changed to see the effect this may have on the fibres to 
be produced.  
In addition to those, the risk assessment of the CQAs against the process parameters can be 
performed. It has well established that the process parameters voltage, flow rate and distance 
between the needle and collector have a very high risk towards the responses. However, these 
will be tested to understand the relationship between them and the CQAs. The operation and 
experiments preforming will be kept constant throughout the experiment, but despite this the 
possibility of human error will still be present, hence this has been left as medium risk. 
An Ishikawa, or cause and effect, diagram is shown in Figure 6. 3, which illustrates the many 
factors that may potentially affect the CQAs, whether as a main cause, direct interaction with 
another parameter or through accumulation of experimental noise. The parameters labelled in 
red will be the factors to be tested and analysed to determine their relationship with the CQAs. 
While the other parameters will be kept as constant as possible. 
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Figure 6. 3 Ishikawa diagram showing the possible factors that may affect the responses 
 
Failure Mode and Effects Analysis (FMEA) is also a form of risk assessment that quantitatively 
analyses and evaluates the level of risk of CQAs being affected by material attributes and 
process parameters (Vohra et al., 2017). Table 6.4 shows the FMEA risk assessment for the 
experiment. The sources of risk are listed and their failure and effects of CQAs or responses are 
described in the table. Each risk was assigned a number between 1 – 5 for the three components 
of risk calculation: Severity of the risk (S), Probability of the risk occurring (P) and 
Detectability of the risk (D), where 1 represents a low risk and 5 would be a high risk. The Risk 
Priority Number (RPN) is the multiplication of S, P and D to give a numerical value describing 
the risk, which was also categorised by colour: green = low risk, amber = medium risk and red 
= high risk (Table 6. 4). 
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Table 6. 4 FMEA Risk Assessment 
CMAs, CPPs 
and other 
sources 
Failure Mode Effect on CQAs and/or responses 
Well 
Controlled? 
S P D 
RP
N 
Selected 
NSAID 
Different NSAID 
may have 
different 
properties 
Different drugs possess different 
properties – may lead to different fibre 
diameters and quality 
No – To be 
tested 
4 3 1 12 
Voltage 
Voltage too high 
or too low 
Low – not enough to generate desired 
electrostatic interaction for good 
electrospinning technique 
High – too much to maintain ideal 
electrostatic interaction with uncontrolled 
whipping process 
No – To be 
tested 
5 3 2 30 
Flow Rate 
Flow Rate too 
high or too low 
Low – Solution ejected too slow to make 
fibre desirably 
High – solution ejected too fast for 
sufficient whipping 
No – To be 
tested 
5 5 2 50 
Distance 
between needle 
and collector 
Distance too high 
or too low 
Low – not enough time to sufficiently 
elongate and dry fibre 
High – Fibre may be too brittle and 
product spread over wider area 
No – To be 
tested 
4 3 2 24 
Drug 
Concentration 
Too high or too 
low 
Any significant deviation between 
formulations will greatly affect all CQAs 
and invalidate results 
Yes – 5% w/w 
and 5% w/v 
5 1 1 5 
Polymer 
Concentration 
Too high or too 
low 
Any significant deviation between 
formulations will greatly affect all CQAs 
and invalidate results 
Yes – 95% w/w 
and 95% w/v 
5 1 1 5 
Polymer 
Molecular 
Weight 
Too low 
May not electrospin as desired, forming 
beaded fibres and droplets 
Yes – high 
molecular 
weight PVP 
4 1 1 4 
Solvents Used 
Different types 
and 
concentrations 
Any significant deviation between 
formulations will greatly affect all CQAs 
and invalidate results 
Yes – 80% v/v 
ethanol and 
20% v/v water 
5 1 1 5 
Operator 
Different 
procedures taken 
More than one operator – some may make 
errors, others may follow different 
method 
Yes – single 
operator 
3 2 1 6 
Density Too high 
Gravitational pull on jet may be too 
strong and may create fibres of poor 
morphology and quality 
No, but easily 
detected 
3 2 1 6 
Surface 
Tension 
Too high or too 
low 
Surface Tension is greatly related with 
applied electric field in jet stream 
formation 
Too high – electrospinning may not occur 
Too low – uncontrolled jet stream 
No, but 
unlikely to be 
high risk as 
using same 
solution 
3 2 1 6 
Electrical 
Conductivity 
Too low 
Too low – Poor fibre morphology with 
likelihood of beads forming 
Should be high Electroconductivity to 
reduce bead formation and promote 
cylindrical and smooth fibres 
No, but easily 
detected 
4 2 1 8 
Temperature 
Too high or too 
low 
Too low – insufficient drying leading to 
increased diameter 
Too high – dries too fast and fibres may 
become brittle and break upon impact 
No, but 
unlikely to 
change 
2 1 2 4 
Humidity Too high 
Causes circular pores to appear on fibre 
surface and may cause coalescence of 
fibres 
No, but 
unlikely to 
change 
2 2 2 8 
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6.6 Method of applying QbD 
 
Prior to starting the experiment, a DoE must first be made. This will be done by using the 
statistical software JMP to generate a full factorial screening design. Since a total of 4 factors 
will be experimented, each with 2 levels, the minimum number of runs required is 16. However, 
centre points are also essential as they help to further understand the results by allowing the 
experiments to include curvature in the results. It is aimed to include 4 centre points. This brings 
the total number of runs to 20. By inputting the responses and factors, along with their 
respective limits, the JMP software constructed a design of how the parameters of the project 
experiments will be tested, as shown in Table 6. 5.  
 
Table 6. 5 Full Factorial Screening design of the project experiments 
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The DoE has now been established and the experiments can be performed by following this 
order. Before the electrospinning process can proceed, the materials must first be weighed using 
an analytical balance. The formulation of the fibre will follow the general formula of: 250mg 
of drug (indomethacin and diclofenac sodium) and 4750mg of PVP. When the correct process 
parameter settings have been set, the process will commence, and the pump will push the 
solution through the silicon tube and into the electrospinning needle, where the electric field 
will be applied, and the solution will be ejected on to the collector as fibres until all of the 
solution is ejected. This will be repeated for all 20 runs, after which testing the samples will 
begin. 
Once all the raw data has been collected and inputted into the JMP software, the data will then 
be simulated and analysed. Predicted vs actual plots will be used to assess the level of deviation 
of the results. The ratio values can help determine the level of noise that may be incorporated 
in the data. Main effects and interactions of high significance can be identified. Profilers will 
be generated to analyse the relationship of the responses with the factors tested. This will 
ultimately lead to a contour plot that will help define a design space, in which working within 
the space will ensure that fibres produced will be of desired quality. Using this design space 
and the information that will be gained alongside, a control strategy can be devised to further 
ensure the quality of the fibres.  
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6.7 Results and discussion 
 
Fibrous films were engineered using two NSAID drugs formulations (Diclofenac Sodium and 
Indomethacin). Stable jetting was determined using a preliminary applied voltage contrasted 
with infusion rate experimental matrix in accordance to Table 6. 4. Different jetting mode has 
been developed regard to material propertied of different drug and therefore, different structure 
of end product for each set up of experiments. However, stable jetting windows were 
determined for NSAID-PVP based formulations at center points.  
Formulated fibres at center point for both NSAID drugs exhibit a smooth surface; albeit with 
slightly variable diameter distributions. Figure 6. 4 show surface morphology of electrospun 
fibrous films obtained using plan view microscopic analysis. Figure 6. 5 shows average diameter 
distributions of selected fibres from each electrospun membrane sample run. The fibre diameter 
was noted to be different for each drug for the similar run. However, both drugs show best 
results at center point runs. Furthermore, indomethacin shows better result for the runs after 
center point especially last two (high voltage and high flow rate) runs with better fibre quality 
compare to the same runs for Diclofenac sodium. The Diclofenac sodium formulation showed 
opposite results for the beginning runs (low voltage and low flow rate). Run 1 showed best 
quality fibre with lowest fibre diameter (low voltage, low flow rate, and lower distance). In 
addition, the runs after center points give not only acceptable fibre diameter but also with 
satisfactory quality. However, at high voltage, high flow rate, and high distance the fibre 
thickness is massively increased and as result the quality of fibre reduced.  
 
 
  
 179 
 
 
 
 
 
 180 
 
 
 
Figure 6. 4 Electron microscope of films samples of Diclofenac sodium (A1 lower quality & 
A2 high quality) and Indomethacin (B1 lower quality & B2 high quality) formulations. 
Quality of fibres identified as Low quality to high quality (1-5). 
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Figure 6. 5 Average fibre diameter size distribution of formulated films (A) and quality of 
fibres across all runs (B) (Comparing both NSAID drugs for each run). 
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Once all the raw data has been collected and inputted into the JMP software the data will then 
be simulated and analysed.  
 
Table 6. 6 JMP table showing the results achieved from the experiments  
 
 
 
Figure 6. 6 Effect summery of most significant effects and interaction 
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Predicted versus actual plots will be used to assess the level of deviation of the results. F ratio 
values can help determine the level of noise that may be incorporated in the data (any value 
close to one is not acceptable). Where, the lower the values, the greater the level of noise 
incorporated into the data. Here the F ratio is reasonably high (42.5927), which confirms the 
assumption that not much noise is present. Furthermore, the ‘RSquare Adj’ Figure 6. 7 illustrates 
how much data from the results was run through the simulation. The red box states that over 
99% of the data was taken into account. This makes it a very reliable model. 
Main effects and interactions of high significance can be identified using the p values. Those 
of a P value that were greater than 0.1 have been ignored. This was because all possible effects 
must be analysed and only the most significant effects and interactions contain a p value lower 
than 0.1. However, the drug with P value of 0.159 has been taken in account as a secondary 
interaction, since its interaction with other factors (e.g. drug*flow rate (µl/min), drug*voltage 
(KV), and drug*voltage (KV)*flow rate (µl/min)) are great. 
The factor interactions Voltage(KV)*Flow rate (µl/min), Drug*Flow rate (µl/min), Flow rate 
(µl/min)*distance between needle and collector (cm), Voltage(KV)*Flow rate (µl/min) 
)*distance between needle and collector (cm), Voltage(KV)*distance between needle and 
collector (cm), Drug*Flow rate (µl/min) )*distance between needle, and Drug*Voltage(KV) 
were the most significant respectively, and interactions between Drug*distance between needle 
(cm), Drug*Voltage(KV)*Flow rate (µl/min), and Drug*Voltage(KV)* distance between 
needle(cm) were also considered highly significant Figure 6. 6. Although drug P value is slightly 
above the 0.1 and is not considered as highly significant but still shows some effect and 
considered in this simulation.  
Profilers will be generated to analyse the relationship of the responses with the factors tested. 
This will ultimately lead to a contour plot that will help define a design space, in which working 
within the space will ensure that fibres produced will be of desired quality. Using this design 
space and the information that will be gained alongside, a control strategy can be devised to 
further ensure the quality of the fibres.  
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Figure 6. 7 Effect summery of fibre diameter (Actual by predicted plot for average fibre 
diameter) 
 
Figure 6. 7 shows an Actual by Predicted Plot of fibre diameter in the red rectangle, which depicts 
the extent of deviation of the actual results (black dots) from the predicted result space (red line 
and red shaded area). Here the deviation is very low, where, all actual results falling within the 
predicted result space. This means the set of results obtained is highly accurate, the process is 
very robust, and the variance of the error was constant. This is further backed by the ‘RSq’ 
value of 0.99 under the Plot. 
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Figure 6. 8 Effect summery of fibre quality (Actual by predicted plot for average quality of 
fibre)  
 
The spread of data in the results obtained for average quality of fibre was satisfactory. This can 
be seen by the red shaded area, where all actual results fall into predicted area. Although there 
is a fair amount of variation in the quality of the fibre, however they were all still within limits. 
This is further backed by the ‘RSq’ value of 0.93 under the Plot. This variation may be due to 
different operation electrospinning equipment or environment that fibres have been produced. 
However, Figure 6. 8 states that over 93% of the data was taken into account. This makes it a 
very reliable model. 
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Figure 6. 9 Profilers showing the optimum conditions for each drug. (Effect of voltage, flow 
rate, and distance of needle from collector against desirability, quality of fibre, and fibre 
diameter (grey area is standard error).  
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Figure 6. 9 illustrates the relationship between the factors and how they affect the desirability 
and response of the experiment. At avarage ( centre point) voltage, high flow rate, and lower 
distanse between needle and collector, the desirability is high for Diclofenac sodium, with 
average fibre quality and diameter likely to be within limits. However, increasing the distance 
between needle and collector will reduce the desirability, while reduce fibre quality and also 
increasing fibre diameter. The same events occur with high flow rate, where desirability also 
decreases. Flow rate greatly effect fibre quality and fibre diameter.  
The desirability and response of experiment was slightly different for indomethacin. Although 
operation voltage is almost same for both drug for high desirability, but indomethacin had 
higher desirability with higher flow rate, where fibre quality and diameter likely to be within 
limits. However, reducing the voltage will signefectly reduce the desirability, while reduce fibre 
quality and also increasing fibre diameter. In jeneral,  
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Figure 6. 10 Design spaces with Flow Rate against Voltage; (top row) Indomethacin, (bottom 
row) Diclofenac Sodium, (left column) at 5cm distance, (middle column) 12.5cm and (right 
column) 20cm 
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Figure 6. 10 shows the predicted contour plot of the factors flow rate and voltage, with the limits 
of the responses already included. This helps define the design space of the process, where 
working within this multidimensional space ensures that the end product will be made to the 
desired and required qualities.  
In the image shown, fibre diameter (red) and quality of fibre (blue) affect the design space 
within the ranges used for the factors that were assessed. Contour plot helps to get an idea of 
the design space, of which the product will achieve its target if working within the limits of the 
design space (white area). If the operation kept in the white area the product desirability is 
certain. Formulation with diclofenac sodium shows most desirable conditions and opens the 
design space into a wider area compare to formulation with indomethacin. However, a common 
design space can be achieved from both contour plot which can predict high desirability for 
both formulations.  
Through the use of a risk-based approach from the foundations of product and process 
understanding, a Control Strategy was created, as shown in Table 6. 7. It describes many aspects 
of the process that the operator can control to ensure the process is always within the acceptable 
limits of the CQAs.  This helps to further maintain the process within the Design Space in order 
to secure the deliverance of electrospun fibres to the desired quality consistently.  
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Table 6. 7 Control Strategy for the Electrospinning of fibres 
Control Strategy 
Element 
Included 
(Y/N) 
Rationale 
Input Material 
Controls 
Y 
Use only the same materials with the same concentrations. 
Replacing one, adding a new material or altering the concentrations 
will affect the CMAs, thereby affecting the CQAs and responses, 
and so would require characterisation tests to be done and a repeat 
of the experiment to obtain better understanding to form fibres of 
assured quality 
Procedural 
Controls 
Y 
Ensure each run is performed for the same length of time and 
method is followed consistently within chosen Design Space.  
Process 
Parameter 
Controls 
Y 
The parameters chosen must be within the chosen Design Space to 
ensure product quality. Ensure Distance of 5cm is used if both 
INDO and DICLO Fibres are to be produced with the same 
parameter settings 
In-Process Tests N Not required as electrospinning is a one-step technique 
Specification Y 
Should meet QTPP requirements and within Design Space limits for 
Fibre Diameter and Quality of Fibre to promote surface area, 
bioavailability, stability, porosity etc. 
Process 
Monitoring 
Y 
Observe process to ensure solution is being ejected with proper 
spray pattern and avoid forming droplets, dried fibres at needle tip 
and any blockages within apparatus 
Characterisation 
and 
Comparability 
Y 
Formulation and fibres must be thoroughly characterised to gain 
sufficient information on its properties, especially Fibre Diameter. 
Fibre products must be compared and analysed between runs via 
SEM analysis to estimate the Quality of Fibre 
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6.8 Conclusion 
 
QbD is the heritage of the experience achieved from manufacturing industries even though 
considered as new drug development.  QbD allows the measurement and assessment of 
different parameters and their effects on critical properties of the methodology and furthermore 
support the importance of scientific knowledge to improve and optimise methodologies.  
The study was performed to find the best factorial combination to get the best possible fibre 
quality with desire diameter when producing NSAIDs drug for buccal delivery and how robust 
the manufacturing process is by using QbD. This was found to be This was found to be if the 
flow rate stays within the range of 5-15 (µl/min), and voltage stay between 13.5 -17.5 (KV), 
the best quality fibre with desirable dimeter will be achieved. As a result, the process is a robust 
and reliable. Although these experiments allowed some understanding of the formulation and 
the process effects on the quality of the final product, further experiments and analysis with 
new drugs are needed to be carried out in order, to obtain better results and design space.  
All design spaces can be used with the respective drug and parameters separately, while the 
design space at 12.5cm would be most suitable if the same parameter settings were to be used 
for both drugs. In future, verification studies could be done, along with a complete control 
strategy. A wider range of factors, such as more drug levels and multiple polymers, could also 
be studied to obtain better process and product understanding. 
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Chapter 7 General conclusion and future prospective 
 
7.1 General conclusion 
 
The overall results suggest that EHDA technique has potential for development of NSAID 
formulations for buccal delivery system. However, suitable polymeric matrix to function as a 
degradable and stable drug carrier is needed. A selection of co-polymers in conjunction with 
NSAID drugs and PVP (main polymer) were analysed.   
The effect of co-polymers on the encapsulation and release was processed. Although each co-
polymer shows an effect on the EHDA system and electrospinning of the formulation, 
therefore, for each formulation the EHDA system needed to be optimised. Furthermore, the 
resulting electrospun were characterised using various techniques. The NSAIDs electrospun 
were found to be made up of fibres with diameter in range of nanometre size. The results also 
show that various formulation of buccal patches containing NSAID drugs can be easily 
engineered by mean of ES method into the amorphous state.  
Furthermore, the X-ray studies demonstrate that NSAID drugs which was associated with the 
fibre was in an amorphous state and therefore molecularly dispersed within the matrix. As can 
be compared with the cast technique which is the NSAID drugs show the crystallinity from 
their X-ray studies.  
The in vitro release of NSAID drugs was regulated by the hydrophilicity/hydrophobicity of co-
polymers in the formulations. This study provides a method to design novel NSAID-polymer 
hybrid electrospun mats exploited for buccal delivery.  
EHDA system parameters and their effect of critical properties of the methodology was 
assessed and measured by QbD therefore gain best possible fibre quality with desire diameter 
NSAID formulations. This was found to be if the flow rate stays within the range of 5-15 
(µl/min), and voltage stay between 13.5 -17.5 (KV), the best quality fibre with desirable 
dimeter will be achieved. As a result, the process is a robust and reliable. 
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7.2 Future work 
 
In this study, it has been shown that EHDA can provide a reliable fibre film for the purpose of 
encapsulation of the NSAID drugs for buccal application. The concept of EHDA has been 
highlighted in this work, however, future work required necessary to highlight the potential of 
buccal film produced for buccal application. The impact of produced film on cell culturing will 
be core investigation of future study.  
Limited polymer and co-polymer were assessed during this study. There are many natural and 
sensitive polymers which were used in buccal (e.g. tablets, patch, gel) formulation. 
Characterisation of more range of polymer may demonstrate more positive results. It is possible 
to coaxial the drug with extra polymer to capsulate the main formulation in case slow release 
required (prolonged the release by extra coating) 
It might be ideal to perform experiments with same formulation but with different technique to 
investigate the variation and drug encapsulation. Hence analysis of the end point product can 
provide more in-depth information about each technique and as a result validate the EHDA. 
This instrument is new and need to be investigated further with different formulation.  
As during this work all the aspect of EDHA kept constant, it is ideal to investigate more in 
depth the parameters which has high effect on the final product (voltage, flow rate, and distance 
to collector).  
 
 
 
 
 
 
 
